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Abstract
Cholesterol gallstone formation is a multifactorial process involving a multitude of metabolic pathways. The primary pathogenic factor is
hypersecretion of free cholesterol into bile. For people living in the Western Hemisphere, this is almost a normal condition, certainly in the
elderly, which explains the very high incidence of gallstone disease. It is probably because the multifactorial background genes responsible
for the high incidence have not yet been identified, despite the fact that genetic factors clearly play a role. Analysis of the many pathways
involved in biliary cholesterol secretion reveals many potential candidates and considering the progress in unraveling the regulatory
mechanisms of the responsible genes, identification of the primary gallstone genes will be successful in the near future.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cholesterol gallstone disease is one of the most common
disorders of the gastrointestinal tract in the Western Hemi-
sphere. A number of independent risk factors for gallstone
disease have been identified: age, gender, pregnancy and
parity, chronic medication with estrogens and fibrates,
obesity, rapid weight loss, pre-existing disease [diabetes
mellitus, Crohn’s disease, resection of terminal ileum,
Gaucher disease, Down syndrome (DS)] and states associ-
ated with gallbladder stasis such as spinal cord injuries,
prolonged fasting, long-term total parenteral nutrition, ther-
apy with ocreotide analogues or somatostinoma and low
physical activity. None of the listed risk factors explains the
family clustering of either gallstone disease or the ethnic
influences indicating involvement of genetic factors as a
separate additional risk factor. The primary event on the way
from gallstone free bile to cholesterol gallstones is super-
saturation of bile with cholesterol. Saturation of bile with
cholesterol is critically dependent on secretion rates of
biliary lipids. Genes controlling the secretion rates are thus
the first natural candidates.
Additional defects—gallbladder hypomotility, acceler-
ated cholesterol crystallization rate and mucus hypersecre-
tion—appear simultaneously in patients with cholesterol
gallstone. These additional defects may be balanced differ-
ently in patients with solitary and multiple stones. Genes
involved in control of gallbladder motility, secretion of
biliary mucin and possibly non-mucin proteins represent
the second source of the potential candidate genes.
The evidence for the genetic background of cholesterol
gallstone disease in humans is mostly indirect and is based
on geographic and ethnic differences, family and twin
studies. Disposition to formation of cholesterol gallstones
in humans is multifactorial and no pattern of inheritance
fitting to the Mendelian pattern could be demonstrated in
most cases. With the exception of multidrug resistance
protein 3 (MDR3) and 7a-hydroxylase deficiency reported
in the recently published studies of Rosmorduc et al. [1],
Jacquemin [2], and Pullinger et al. [3], no gene mutation or
polymorphism has been associated with cholesterol gall-
stones in humans. Fortunately, the mammalian genome is
highly conserved and the vast majority of human genes have
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their orthologues in other mammals. As a consequence, a
similar genetic background might be expected in animal
models of numerous human diseases. Mouse models pro-
vide comprehensive genetic resources and offer many
possibilities for genetic manipulations. In addition, quanti-
tative trait locus analysis may be used for identification of
the primary genetic defects responsible for the phenotype of
a multifactorial disease under controlled conditions. For
these reasons, mouse models became the model of choice
for studies of the genetic background of gallstones [4]. The
first inventory of candidate mouse Lith genes has recently
been reviewed by Lammert et al. [5].
2. Scope of the review
In this overview, we will focus on the predominant form
of gallstone disease, formation of cholesterol stones.
Although in addition to lipids also proteins may play a role
in the etiology (see review in Ref. [6]), we will focus on the
main biliary components cholesterol, phospholipid and bile
acids. We will first discuss the metabolic pathways involved
in metabolism of these lipids. Subsequently, we will attempt
to couple this information to what is known from human
epidemiology and genetic studies. Finally, a brief overview
of the genetic diseases associated with gallstones will be
presented.
3. Candidate genes involved in regulation of biliary
cholesterol secretion
3.1. Recourses of biliary lipids
Since cholesterol in bile is solubilized in a complex
mixture of bile salts and phospholipid, the concentration
of these factors plays an important role in regulation of
cholesterol saturation as given by the biliary cholesterol
saturation index (CSI). The increased CSI observed in
patients with cholesterol gallstones may result from
increased biliary cholesterol secretion but may also be
caused by decreased bile salt or phospholipid secretion or
by a combination of these parameters.
The main organ for cholesterol metabolism is the liver. It
regulates the synthesis of cholesterol, the conversion of
cholesterol into bile acids, the secretion of cholesterol into
bile either directly or as bile salts, the uptake and hydrolysis/
metabolism of plasma cholesterol/esters in the form of high-
density lipoprotein (HDL) or low-density lipoprotein (LDL)
particles, the esterification of excess of free cholesterol, and
the secretion of cholesterol into plasma. The source of
cholesterol destined for biliary secretion is as yet not fully
known. The major part is thought to be derived from a pre-
existing hepatic cholesterol pool; however, this pool is not
well defined. One of the sources, although this represents
only a small fraction (5–20%) of total biliary cholesterol, is
cholesterol from hepatic de novo cholesterol synthesis [7–
9]. The second source of biliary cholesterol is cholesterol
derived from plasma lipoprotein particles of which HDL
seems to be the major supplier [10]. However, Abca1
knock-out mice which are deficient in HDL show no
decrease in biliary cholesterol output, suggesting that either
HDL may not be that important or its role can easily be
taken over by a parallel mechanism [11]. In contrast to
HDL, no direct secretory pathway of LDL or VLDL
cholesterol into bile has ever been reported. Bile acids are
thought to be preferentially formed from newly synthesized
cholesterol; however, depending on the conditions also
cholesterol from plasma lipoprotein particles may be used
as a precursor for bile acid synthesis [12,13]. Increased
biliary cholesterol secretion may result from the increase of
de novo synthesis, the decreased conversion of cholesterol
into bile acids, the decreased esterification or the increased
uptake of cholesterol from plasma lipoprotein particles. In
addition, the amount of phospholipids and bile acids as well
as the pattern of secreted bile salts is important for regu-
lation of cholesterol secretion into bile. Clearly, defects in
genes encoding proteins involved in all these processes may
play an important role in the formation of cholesterol
gallstones.
3.2. Cholesterol synthesis
Although newly formed cholesterol contributes only
partially to biliary cholesterol, the increased cholesterol
synthesis may still be one of the mechanisms involved in
the formation of cholesterol gallstones. The key enzyme in
de novo cholesterol synthesis pathway is 3-hydroxy methyl-
glutaryl-Coenzyme A (HMG-CoA) reductase [14]. Both the
gene expression and the activity of the enzyme are regulated
by intracellular cholesterol concentrations via cholesterol-
derived oxysterols. Oxysterols function as regulators of the
activity of the sterol regulatory element binding proteins
(SREBPs) (see below). These transcription factors regulate
the expression of all genes in the cholesterol biosynthetic
pathway [15]. Rodents fed a high-cholesterol diet accumu-
late cholesterol in the liver. Their cholesterol synthesis is
reduced by decreasing the transcription of the genes encod-
ing for HMG-CoA reductase [16], HMG-CoA synthase
[17], farnesyl diphosphate synthase [18] and squalene
synthase [19]. The activity of HMG-CoA reductase is
controlled by regulation of the half-life of the protein and
the state of phosphorylation of the protein. In rodents, a
relation seems to exist between HMG-CoA reductase
expression/activity and gallstone formation. The expression
of HMG-CoA reductase in the liver was properly down-
regulated in the more gallstone-resistant AKR strain upon
feeding a high-cholesterol diet [20], whereas in C57L/J mice
which are susceptible for gallstone formation, the expression
of HMG-CoA reductase remained unchanged. Furthermore,
in hamsters fed a cholesterol gallstone-inducing diet, the
activity of HMG-CoA reductase increased enormously even
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long before the appearance of gallstones [21]. In humans,
however, a relation between the activity of HMG-CoA
reductase and biliary cholesterol secretion is less clear.
Ahlberg et al. [22] determined the HMG-CoA reductase
activity in the liver of 55 patients (10 with adenomyoma of
the gallbladder wall, 45 with cholesterol gallstones). Bile of
these patients was supersaturated with cholesterol. HMG-
CoA reductase activity in gallstone patients, however, was
not different from that seen in the gallstone-free controls. In
addition, in the gallstone-free control group and in the group
of bile acid-treated gallstone patients but not in untreated
gallstone patients, the saturation of bile correlated with the
activity of HMG-CoA reductase in the liver. Studies of
Maton et al. [23] showed that there was no correlation
between the activity of HMG-CoA reductase and the biliary
cholesterol output in nine patients. Moreover, a similar
activity of HMG-CoA reductase was found in patients with
gallstones and gallstone-free patients even though the satu-
ration of the gallbladder bile was higher in gallstone patients
[24]. A possible caveat in these studies is that the measured
in vitro activity of the enzyme may not reflect the activity of
HMG-CoA reductase in the intracellular milieu.
3.3. Cholesterol esterifying enzymes
Excess of intracellular cholesterol can be esterified by
acyl-CoA cholesterol acyl-CoA transferase (ACAT) [25,26].
Cholesterol esters are then stored in cytosolic droplets or are
secreted into the circulation as part of lipoprotein particles.
Two Acat genes have been identified: Acat1 and Acat2 (or
Soat1 and Soat2, respectively). Although Acat1 is expressed
in many tissues [26,27], the highest levels in mice were
found in macrophages and adrenocortical cells, whereas
only low expression was seen in the liver and the small
intestine [28,29]. In mice lacking the Acat1 gene, choles-
terol esters were absent in the adrenal glands and peritoneal
macrophages [30]. In the liver, however, cholesterol ester-
ification activity was still present suggesting the existence of
a second Acat gene.
Acat2 was identified in 1998 and the expression was
shown to be restricted to liver and intestine [31–33]. Acat2-
deficient mice [34] had indeed a reduced cholesterol ester-
ifying activity in the small intestine and liver. On a normal
diet, Acat2 / mice showed no major differences in
cholesterol metabolism compared to wild-type mice. In
contrast, a high-cholesterol/high-fat (HC/HF) diet reduced
the intestinal cholesterol absorption in Acat2 / mice
to 15% of that of wild-type mice. Moreover, the concen-
trations of cholesterol in gallbladder bile were 30% lower in
Acat2 / mice compared to wild-type mice. This was
reflected in the formation of gallstones: all wild-type mice
but none of the Acat2-deficient mice fed the HF/HC diet for
3–6 weeks developed cholesterol gallstones. Even after 3
months, only 3 out of 14 Acat2-deficient mice had a few
stones [34]. These results in mice seem to contradict the
human situation in gallstone formation, since Smith et al.
[35] demonstrated that patients with cholesterol gallstones
have decreased hepatic ACAT activity. Buhman et al. [34]
argue that this is not per se contradicting because Acat2
deficiency in the intestine lowers cholesterol absorption,
which may then decrease the flow of cholesterol to the liver
resulting in the decreased biliary cholesterol output. Thus, a
specific deficiency of Acat2 in the liver may increase the
risk of gallstone formation. However, in the human liver,
ACAT1 rather than ACAT2 seems to be higher expressed
[36], and might therefore play a more important role than
ACAT2 in esterification of hepatic cholesterol.
3.4. Cholesterol ester hydrolases
Cholesterol esters derived from LDL particles are hydro-
lyzed by the action of acid lysosomal cholesterol ester
hydrolase. Neutral cholesterol ester hydrolase is responsible
for hydrolysis of cholesterol esters stored in lipid droplets.
In cholesterol-fed rats, the activity of hepatic neutral
cholesterol ester hydrolase as well as mRNA levels were
decreased [37]. Moreover, inhibition of cholesterol biosyn-
thesis by lovastatin and stimulation of biliary cholesterol
secretion by chronic biliary diversion increased both the
activity and the expression of the enzyme, whereas cheno-
deoxycholate feeding decreased this. These data suggest
that neutral cholesterol ester hydrolase responds to changes
in cholesterol flux through the liver [37]. The mechanism
by which the enzyme is regulated is unknown. The
increased activity and/or expression of neutral cholesterol
ester hydrolase may contribute to the enhancement of
biliary cholesterol secretion and hence formation of cho-
lesterol gallstones.
3.5. Bile salt biosynthesis
As already mentioned above, formation of cholesterol
gallstones may also be induced by the decreased output of
bile salts and/or the shift toward the more hydrophobic bile
salt species, thereby changing the CSI in bile. Excess of
hepatic cholesterol can be converted into bile salts via two
pathways: the classic or neutral pathway and the alternative
or acidic pathway. Cholesterol 7a-hydroxylase (CYP7A1)
plays a key role in the classic pathway, whereas sterol 27-
hydroxylase (CYP27) is the regulatory enzyme in the acidic
pathway. The neutral pathway is active exclusively in the
liver. The alternative pathway, at least CYP27, is present in
almost all tissues.
Sterol 12a-hydroxylase (CYP8B1) controls the ratio of
cholic acid (CA) and chenodeoxycholic acid (CDCA) syn-
thesis in both neutral and alternative pathways and thereby
regulates the bile salt hydrophobicity index. The biliary
cholesterol secretion rate depends on the hydrophobicity of
the bile salt. Therefore, via this seemingly indirect way,
CYP8B1 may regulate biliary cholesterol output. A fourth
cytochrome P450 (CYP) involved in regulation of the rate
of cholesterol secretion into bile is oxysterol 7a-hydrox-
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ylase (CYP7B1). This enzyme catalyzes the second step in
the alternative pathway. In humans, conversion of choles-
terol to bile acids accounts for approximately half of the
daily elimination of cholesterol from the body. The major
portion of the remaining 50% is eliminated as free choles-
terol [38,39]. In rats, up to 50% of the total bile acid
synthesis may occur via the alternative pathway [40–42].
This is not the case in healthy humans [43] where only less
than 10% of the total bile acid synthesis appeared to be
synthesized via this pathway [44,45].
The increased delivery of cholesterol to the liver leads
to increased bile acid synthesis via the classical pathway
[46–48] through up-regulation of CYP7A1 induced by the
oxysterol receptor liver X receptor (LXR) in many species
[49]. However, hepatic overload of cholesterol, either by
dietary cholesterol or by increased hepatic cholesterol
synthesis, induces different responses of CYP7A1 in
different species. In rodents, cholesterol feeding increases
the expression of CYP7A1 and the conversion of choles-
terol into bile acids. Rodents therefore are rather resistant
to diet-induced hypercholesterolemia [47]. In rabbits [50],
hamsters [51], and Green Monkeys [52], CYP7A1 is not
induced in response to the high load of dietary cholesterol
which leads to the development of hypercholesterolemia
and atherosclerosis in these animals. Most humans respond
to excess of cholesterol similarly to rabbits and hamsters
resulting in increased plasma LDL-cholesterol levels and
atherosclerosis, although in some humans, an increase in
bile salt synthesis has been reported [53]. This difference
in response of CYP7A1 to the high-cholesterol diet
between rodents and humans is explained by the lack of
binding of LXRa to the human CYP7A1 promoter due to
a single nucleotide change in the human LXRE [54]. In
Cyp7a1 / mice, the rate of the bile acid synthesis and
the size of the bile salt pool were reduced by approxi-
mately 60% and 80%, respectively. This significant change
affected the intestinal absorption of cholesterol and the
fecal excretion of bile salts was decreased as well in these
mice. In contrast, both the total fecal cholesterol excretion
and the total fecal sterol excretion were increased. How-
ever, compensatory increases in sterol synthesis took place
in the liver and the intestine. Therefore, the reduced
cholesterol absorption did not affect plasma and tissue
cholesterol levels [55]. The disruption of Cyp7a1 did not
change the molar ratio of cholesterol to total lipids in
gallbladder bile and the effect on the formation of gall-
stones would probably be minimal. In hamsters overex-
pressing Cyp7a1 and fed a high-cholesterol diet, the rate of
bile acid synthesis increased [56]. Similarly, CYP7A1
overexpression in HepG2 cells and primary human hep-
atocytes increased bile acid synthesis via the classic path-
way and suppressed cholesterol synthesis [57], whereas in
cholesterol-fed CYP7A1 transgenic mice lacking the
endogenous Cyp7a1 / gene, LXR could not bind the
CYP7A1 promoter and failed to increase the expression of
CYP7A1 [58]. These studies showed that manipulation
with CYP7A1 expression could change non-responsive
species into responsive ones and vice versa. The rate of
bile acid synthesis and the activity of CYP7A1 protein are
tightly feedback inhibited by bile acids returning to the
liver via the enterohepatic circulation of bile. Hydrophobic
bile acids are the main active bile acid species in this
respect [47,59–61]. The CYP7A1 promoter region contains
a bile acid response element (BARE) that has been
identified as a hepatocyte nuclear factor 4 (HNF4) binding
site [62]. This binding site overlaps with the binding site
for several other factors from the family of monomeric
nuclear receptors [63]. In both mice and human HepG2
cells, CYP7A1 expression is repressed by bile acids via
the activation of the bile acid receptor FXR, the subse-
quent activation of the short heterodimeric partner (SHP)
and following repression of the liver receptor homolog
LRH1 [64–66]. In HepG2 cells, HNF4 has been shown to
compete with LRH1 for binding on their overlapping
binding sites on the CYP7A1 promoter [64]. Gupta et al.
[67] reported that besides FXR-mediated down-regulation
of CYP7A1 by bile acids, also the Jun kinase signaling
pathway is activated and plays an additional role in down-
regulation of CYP7A1. Multiple pathways are thus
involved in regulation of the expression of CYP7A1 and
the control of the rate of the synthesis of bile salts.
Recently, Pullinger et al. [3] reported high levels of LDL
cholesterol in three patients with a homozygous mutation
in CYP7A1. In one patient, the hepatic cholesterol content
was increased, whereas fecal excretion of bile salts was
absent. In addition, two of the three patients studied had
hypertriglyceridemia and premature gallstone disease.
Sterol 27-hydroxylase (CYP27) is an ubiquitously
expressed mitochondrial enzyme that catalyzes the first step
in the acidic pathway of bile acid synthesis and the 27-
hydroxylation of bile acid intermediates in the neutral
pathway (CYP7A1) [68]. 27-Hydroxycholesterol can com-
pete with cholesterol in the further metabolization and is
also a substrate for CYP7B1, the microsomal oxysterol
hydroxylase [69]. In extrahepatic tissues, CYP27 converts
cholesterol to 27-hydroxycholesterol and 3h-hydoxy-5-cho-
lestenoic acid which are then effluxed, incorporated into
lipoproteins and transported to the liver, where they are
probably metabolized via the alternative pathway into bile
acids [70–73]. In vitro, 27-hydroxycholesterol inhibits
HMG-CoA reductase activity [14,74] and stimulates the
activity of ACAT2 [75], resulting in a reduction of the
intracellular free cholesterol concentrations. Recently, 27-
hydroxycholesterol was identified as a ligand for the nuclear
receptor LXR [76] (see below). In rats, CYP27 expression is
down-regulated in vivo and in vitro by hydrophobic bile
acids [41,77]. In contrast, in rabbits, no effect was seen of
bile acids on the expression of CYP27. Cholesterol, how-
ever, did stimulate CYP27 expression in rabbits [78] which
emphasizes again the differential physiological responses of
pathways involved in cholesterol metabolism in the different
species.
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In humans, mutation of CYP27 leads to the develop-
ment of cerebrotendinous xanthomatosis (CTX), a disease
marked by progressive neurological dysfunction and accel-
erated atherosclerosis [79]. In these patients, bile acid
synthesis and the total bile acid pool are decreased,
whereas cholesterol synthesis is increased. Cyp27 / mice
showed a similar decrease in metabolism of cholesterol to
bile acids and increase in cholesterol synthesis as seen in
humans [80]; however, they did not develop CTX. The
expression of CYP7A1 mRNA in Cyp27 / mice was
increased enormously, whereas the mRNA levels of
CYP7B1 were decreased. Intestinal cholesterol absorption
was also decreased which was compensated by an
increased synthesis of cholesterol in the liver and the
intestine. In gallbladder bile of the Cyp27 / mice, the
cholesterol concentration was unchanged, whereas concen-
trations of bile acids and phospholipids were decreased.
The molar ratios of cholesterol to the other biliary lipids in
gallbladder bile and the risk for cholesterol gallstone
formation in Cyp27 / mice were increased [81]. To
our knowledge, no data on gallstones in CTX patients
have been reported.
Sterol 12a-hydroxylase (CYP8B1), a microsomal cyto-
chrome P450, is responsible for the synthesis of cholic acid.
Sterol 12a-hydroxylase acts at a branch point in the bile
acid pathway determining the ratio of cholic acid to cheno-
deoxycholic acid. This may be important for the formation
of gallstones because CDCA, in contrast to CA, may reduce
the degree of cholesterol saturation in bile. The overall bile
acid hydrophobicity index is important for cholesterol and
bile acid synthesis, intestinal cholesterol absorption, biliary
cholesterol secretion and gallstone formation [82,83]. The
expression of CYP8B1 is regulated by a negative feedback
control by hydrophobic bile acids [84] in a similar manner
to CYP7B1. In contrast, CYP8B1 expression was up-regu-
lated by hydrophilic bile acids, whereas excess of dietary
cholesterol decreased the expression of CYP8B1 by 40%
[84]. Overexpression of Cyp8b1 in rats resulted in an
increased pool of cholic and deoxycholic acid and a corre-
sponding decrease in the chenodeoxycholic and muricholic
acid pool [85], but the overall rate of bile acid synthesis
remained unchanged.
Oxysterol 7a hydroxylase (CYP7B1) catalyzes the sec-
ond step in the alternative pathway. Mice deficient for
Cyp7b1 / [86] appeared to have normal bile acid syn-
thesis; however, 25- and 27-hydroxysterols accumulated in
serum and in several tissues including the liver. These two
oxysterols have been shown to act as ligands for the nuclear
receptor LXR [76,87] (see below). The levels of plasma and
tissue cholesterol were not changed in the Cyp7b1 / mice
and bile of these mice was not analyzed. Recently, Pandak et
al. [88] reported that CYP7B1 in primary rat hepatocytes is
regulated by bile acids, cholesterol and cAMP in a similar
manner to CYP7A1. In contrast, overexpression of CYP7B1
in these cells did not result in increased bile acid synthesis
suggesting that under normal conditions, the activity of
CYP7B1 is not a rate-limiting step in this pathway. There-
fore, a potential role for CYP7B1 in cholesterol gallstone
formation remains to be investigated.
3.6. Genes involved in intestinal cholesterol absorption
Cholesterol taken up in the intestine originates from diet
and bile. Depending on the species, in most cases, the
biliary pool that undergoes enterohepatic recycling is the
larger of the two. Until recently, very little was known about
the proteins involved in regulation of cholesterol uptake. A
role for the HDL receptor SR-B1 was proposed by Schulth-
ess et al. [89]. Recently, this group also implicated CD36
and a third protein factor which together accounted for most
of the transport activity in isolated brush border membrane
vesicles [90]. In addition to the active transport, there may
be still considerable passive diffusion of cholesterol into the
intestinal epithelial cells and recent data suggest that the net
cholesterol absorption is the result of both uptake and active
secretion back to the lumen. The transporters that have been
implicated in the secretory route belong to the family of
ATP binding cassette (ABC) transporters, that is: ABCA1
[91,92] and ABCG5 and ABCG8 [93–95].
ABCA1 is expressed in the liver but no expression could
be detected in enterocytes under normal conditions [96]. The
subcellular localization of the protein in enterocytes and
hepatocytes has not been reported yet, although in HeLa
cells, a GFP-tagged ABCA1 was detected in intracellular
vesicles and at the plasma membrane [97], whereas in DBGE
cells, basolateral localization of ABCA1 was found [98].
Repa et al. [91] observed an increased intestinal expression
of ABCA1 and a simultaneous inhibition of cholesterol
absorption in mice fed a retinoid X receptor (RXR) agonist.
The strong up-regulation of ABCA1 expression in the
intestine observed was mediated via the nuclear receptor
LXR and indirectly RXR. In contrast, Abca1 null mice
showed only a slightly reduced cholesterol absorption [92].
It is thus not yet clear whether ABCA1 is really instrumental
in the observed inhibition of cholesterol absorption.
The second set of ABC-transporters implicated to have a
role in intestinal cholesterol uptake are the recently identi-
fied ABC-halftransporters ABCG5 and ABCG8 [93–95].
Mutations in either of these genes cause sitosterolemia, a
disease of which one of the hallmarks is the increased
absorption of plant sterols and other sterols including
cholesterol. Neither subcellular localization nor function of
the halftransporters is known at present. Repa et al. [99]
showed that ABCG5 and ABCG8 mRNA were homoge-
neously expressed in enterocytes lining the microvilli.
The multidrug resistance transporter MDR1 has been
reported to play a role in intestinal cholesterol absorption.
Mdr1a and Mdr1b in mice, but only one MDR1 in humans
are expressed in a number of tissues including the apical
membrane of the enterocytes. In cell culture experiments,
MDR1 was associated with the uptake and trafficking of
sterols. Nonspecific inhibitors of MDR1 have been shown
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to inhibit cholesterol synthesis and the esterification of
cholesterol putatively by blocking the trafficking of sterols
from plasma membrane to ER [100–102]. The increased
expression of MDR1 was associated with increased accu-
mulation of cholesterol and enhanced kinetics of cholesterol
esterification in a rat epithelial cell line [103,104]. Recently,
Luker et al. [105] determined that intestinal cholesterol
absorption was not affected in Mdr1a/Mdr1b double knock-
out mice. They did find, however, an increased kinetics of
cholesterol accumulation in the liver after oral administra-
tion of cholesterol. Although the above reports may suggest
a role for MDR1 in intestinal and hepatic cholesterol
handling, the in vitro and in vivo results are of opposite
directions. Therefore, a role for MDR1 in intestinal choles-
terol absorption remains to be elucidated. Biliary lipid
secretion is not affected in Mdr1a/b / mice (R. Ottenhoff,
personal communication).
3.7. Genes involved intracellular trafficking of cholesterol
One of the proteins reported to have a role in intracellular
cholesterol/lipid trafficking and metabolism is sterol carrier
protein 2 (SCP2). The intracellular localization of SCP2 is
still a matter of controversy. A number of studies localize
the protein exclusively in the peroxisomes but others also
reported presence of the protein in the cytosol. A role for
SCP2 in intracellular lipid transport has been proposed in
several studies. Purified SCP2 has been shown to bind
cholesterol and to stimulate interorganellar cholesterol trans-
fer [106] as well as the conversion of free cholesterol into
cholesterol esters [107] and 7a-cholesterol [108,109] and to
stimulate the transfer of sterols among intracellular mem-
branes in vitro [110]. However, SCP2 has been shown to
have a similar or higher affinity for fatty acids and fatty acyl
CoA than for cholesterol [111,112]. Intracellular cholesterol
transport by SCP2 was suggested when Puglielli et al. [113]
showed in cultured fibroblasts, using antisense nucleotides,
that SCP2 increased the transport rate of newly synthesized
cholesterol from the ER to the plasma membrane. Further-
more, overexpression of Scp2 in rat hepatoma cells
enhanced intracellular cholesterol cycling, increased plasma
membrane cholesterol content and decreased cholesterol
esterification and HDL production [114]. By using in vivo
antisense oligonucleotide treatment in rats, a role for SCP2
in the transport of newly synthesized cholesterol in biliary
secretion was suggested [115]. In diosgenin-fed rats in
which cholesterol synthesis was increased, hepatic SCP2
expression was increased as well [115]. In mouse strains
differing in susceptibility to cholesterol gallstone formation
fed a lithogenic (gallstone inducing) diet, SCP2 mRNA and
protein levels correlated with biliary cholesterol secretion
rates [116]. Adenovirus-mediated SCP2 transfer in C57BL/6
mice [117] resulted in decreased plasma HDL cholesterol
levels and increased LDL cholesterol levels. The level of
total plasma cholesterol remained unchanged. Hepatic free
cholesterol levels were increased (1.6-fold) and cholesterol
synthesis was decreased by 40% in AdSCP2 mice. The total
bile acid pool was slightly increased in infected mice but the
composition was not changed. Adenovirus-mediated over-
expression of SCP2 increased the bile flow by 73% due to a
3-fold increase in bile acid-independent bile flow. Biliary
output of bile salts and phospholipids increased by 50–
60%, whereas cholesterol secretion was increased 2-fold.
This led the authors to the conclusion that overexpression of
SCP2 enhanced the enterohepatic circulation of cholesterol
and bile acids due to the increased intracellular cholesterol
cycling.
Scp2/Scpx knockout mice [118] in a gallstone-susceptible
strain (C57BL/6 background) did not show any changes in
plasma or liver cholesterol levels; instead, these mice were
defective in the peroxisomal oxidation of tetramethyl
branched fatty acyl CoAs. Recently, the same group [119]
reported that the Scp2/Scpx / mice have similar biliary
cholesterol secretion rates compared to wild-type mice,
increased bile flow and decreased bile salt secretion rates
on chow diet. Feeding a lithogenic diet resulted in a lower
increase in biliary cholesterol secretion in Scp2 / mice
compared to wild-type mice but the diet still induced
cholesterol gallstone formation in both wild-type and
knockout mice. This suggests that the role of SCP2 in
gallstone formation is not of major importance although in
gallstone patients, higher hepatic levels of SCP2 protein
were found [120].
Intracellular cholesterol transport has also been suggested
to be mediated by liver fatty acid binding protein (L-FABP)
[121,122]. This protein has been shown to bind cholesterol
in vitro and to enhance sterol transport between membranes
[123], although others could not confirm this [124]. The
expression of L-FABP was up-regulated in livers of Scp-2
knockout mice [119].
Caveolin-1 is the main protein of caveolae, which are
plasma membrane invaginations that are highly enriched in
cholesterol and sphingomyelin. Caveolins/caveolae have
been implicated in cell signaling [125], transcytosis
[126,127] and in regulation of intracellular cholesterol
transport [128] (reviewed in Refs. [125,129]). In the plasma
membrane, caveolin-1 interacts with cholesterol [130,131]
and the protein is expressed in a variety of cell types and
tissues including the liver where it is present in both the
sinusoidal and canalicular membrane of the hepatocyte
[132–134]. The transcription of CAV1 is under the positive
control of cholesterol via the SREBP pathway (see below),
resulting in increased transcription of CAV1 when intra-
cellular cholesterol levels are high [135]. In vitro, caveolin-1
has been shown to form a complex with chaperone proteins
which may facilitate the transport of cholesterol from the ER
to the plasma membrane [136]. In addition, caveolae
appeared to be able to mediate cellular cholesterol efflux
to plasma [137], whereas in hepatocytes, the scavenger
receptor class BI (SR-BI) has been shown to be associated
with caveolae indicating their role in cholesterol uptake
[138]. A role for caveolin-1 in biliary cholesterol secretion
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was suggested from results from studies in inbred mice in
which expression of caveolin-1 was reported to be up-
regulated during cholesterol gallstone formation [20],
whereas expression of caveolin-2 was increased during
hypersecretion of cholesterol by diosgenin feeding [139].
Recently, two groups reported the generation of Cav1
knockout mice [140,141]. Unfortunately, the role of caveo-
lin in biliary secretion was not investigated. The composi-
tion of lipoproteins was studied only by Drab et al. [140]
and was not significantly changed in Cav1 / mice.
In adenovirus-mediated overexpression of CAV1 in
C57Bl/6J mice [142], caveolin-1 protein was localized on
the basolateral membrane of hepatocytes, and induced a
f 2-fold increase in plasma HDL-cholesterol levels. CAV1
overexpression inhibited the selective HDL-cholesteryl ester
uptake mediated by SR-BI in cultured primary murine
hepatocytes infected with AdCAV1. This supported the idea
that caveolin-1 may play a role in HDL-cholesterol metab-
olism.
The Niemann-Pick C1 (NPC1) protein is a transmem-
brane protein containing a sterol sensing domain homolo-
gous to the domains found in HMG-CoA reductase, SCAP
and Patched [143]. Defects in the NPC1 gene result in
intracellular accumulation of unesterified cholesterol
together with several other lipids in the lysosomal com-
partment and cholesterol export from the lysosomes may
be inhibited [144]. The exact function of NPC1 is not
known but it was suggested to be involved in intracellular
cholesterol trafficking from the lysosomes to a cholesterol
pool, which can be used for bile acid synthesis and biliary
cholesterol secretion. A role in transport of cholesterol to
the canalicular membrane for biliary cholesterol secretion
was suggested when Npc1 / mice fed a high-cholesterol
diet failed to up-regulate biliary cholesterol secretion
[145].
3.8. Genes involved in cellular uptake of cholesterol
Apolipoprotein AI (ApoAI) is the main lipoprotein on
HDL. Apoa1 knockout mice had low plasma HDL-choles-
terol levels [146,147] and their rate of hepatic cholesterol
synthesis was 50% lower than in wild-type mice. The total
body cholesterol content and hepatic cholesterol concen-
trations were not changed. In Apoa1 / mice, also the rate
of bile acid synthesis was normal and the absolute concen-
trations of bile acids, phospholipids and cholesterol in
gallbladder bile of Apoa1 / mice were not different from
wild-type mice [147] despite the lower plasma HDL levels
and reduced cholesterol synthesis. In contrast, Apoa1 over-
expressing mice have been reported to have a 2-fold
increase in biliary output of bile acid and cholesterol
[148]. The similar cholesterol concentrations in gallbladder
bile of both wild-type and Apoa1 knockout mice show that
at least that HDL-cholesterol levels do not regulate biliary
cholesterol secretion, which is consistent with observations
in the Abca1 null mice.
ApoE is the major protein component of chylomicrons
(CM) and serves as the high-affinity ligand for the LDL-
receptor and LDL-receptor-related protein [149]. When
wild-type mice and Apoe knockout mice were fed a
0.02% and 0.5% cholesterol diet, the percentage of intestinal
cholesterol uptake in Apoe / mice was higher than in
wild-type mice [150]. In Apoe knockout mice, biliary
cholesterol and bile salt secretion were not changed on
chow diet. Biliary cholesterol secretion increased during
either a high-cholesterol or lithogenic diet but the increase
was lower in Apoe / mice compared to wild-type mice
[150,151]. Biliary bile salt secretion, however, was not
much affected in Apoe knockout mice on the lithogenic
diet. As a result, the saturation of bile with cholesterol in
wild-type mice increased and exceeded the maximal
capacity of gallbladder bile to solubilize cholesterol by
61%. In Apoe null mice fed the lithogenic diet, the CSI
did not change significantly [150] which might explain the
decreased gallstone formation compared to the wild-type
mice. These reports suggested a role for ApoE in the
formation of cholesterol gallstones. Hepatic cholesterol
concentrations were increased in Apoe-deficient mice com-
pared to wild-type mice; thus, decreased hepatic cholesterol
could not be responsible for the decreased secretion of
biliary cholesterol in response to a high-cholesterol diet.
ApoE might play a role in controlling the availability of
dietary cholesterol in the liver (as a component of CMs) for
bile secretion, and furthermore, it might regulate the bile
cholesterol/bile salt molar ratio, thereby controlling the
cholesterol saturation in gallbladder bile. Absence of ApoE
could alter intracellular trafficking of cholesterol to specific
pools necessary for cholesterol transport to the canalicular
membrane [152]. An alternative option could be that ApoE
present in bile [153] might play a role in regulating
cholesterol crystallization and growth. In humans, contra-
dictory studies have been published for ApoE on this
subject [153–156]. Juvonen et al. [153] and Bertomeau et
al. [154] found a positive correlation between ApoE4
phenotype and cholesterol crystals in bile, fast cholesterol
crystallization in gallbladder bile and a higher cholesterol
content in gallstones in patients bearing this polymorphism.
However, this correlation could not be confirmed by Van
Erpecum et al. [155] and Fischer et al. [156]. Kesaniemi et
al. [157] showed that the percentage of dietary cholesterol
absorption decreased in the order of ApoE polymorphism
E4 >E3>E2, and also showed that the fecal excretion of
cholesterol tended to be higher in individuals having the
ApoE2 polymorphism compared with E3 or E4 individuals
[158].
The SR-BI [159] binds HDL with high affinity [160] and
has the highest expression levels in the liver and steroido-
genic tissues. At lower levels, it is expressed on the apical
surface of the small intestine [161]. The expression of SR-
BI in these tissues is coordinately regulated with cholesterol
metabolism [162–164]. In the promoter of SR-BI, a number
of binding sites for transcription factors have been identified
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including C/EBP, SF1 and SREBP1 (reviewed in Refs.
[163,165]). SR-BI facilitates the cellular uptake of choles-
terol (cholesteryl esters) from HDL. The mechanism by
which this occurs is not yet known. The present belief is that
only free cholesterol and cholesterol esters are taken up but
not the apolipoproteins and that the particle is not internal-
ized. However, recently, Silver et al. [166] reported recently
that ApoAI is taken up and recycled. As indicated above,
HDL cholesterol has been suggested to be preferentially
utilized for direct biliary secretion [167–170] and the
generation of Srb1 knockout and overexpressing mice
seemed indeed to imply an important role for SR-BI in
biliary cholesterol secretion. Hepatic overexpression of Srb1
[169] in mice reduced plasma levels of HDL cholesterol and
increased biliary cholesterol concentration, whereas bile
acid or phospholipid contents were not changed. The
opposite characteristics were observed in mice with a
disrupted Srb1 gene [171,172]: total plasma cholesterol
levels were elevated and biliary cholesterol secretion was
reduced without alteration of biliary bile acid secretion, bile
acid pool size or fecal bile excretion [171–173]. This
suggested a model in which hepatic SR-BI mediates the
transfer of cholesterol from plasma HDL to bile for excre-
tion and in which overactivity of SR-BI may induce
increased biliary cholesterol secretion coupled to decreased
plasma HDL levels and hence could play a role in gallstone
formation.
3.9. Canalicular membrane lipid transporters
Bile formation is regulated by several transmembrane
transport proteins belonging to the ABC-transporter family.
Since these ABC-transporters are responsible for the secre-
tion of the predominant biliary components over the canal-
icular membrane, changes in the expression and/or activity
of these proteins may result in an alteration of bile compo-
sition, which may influence gallstone formation. Until now,
three ABC-transporters localized at the canalicular mem-
brane have been found to be involved in the secretion of the
main lipid components of bile. The bile salt export pump
(BSEP, or SPGP, or ABCB11) regulates the secretion of bile
salts into bile. BSEP expression is restricted to the canal-
icular membrane of the hepatocyte. The second ABC-trans-
porter is Mdr2 in rodents and MDR3 (ABCB4) in humans.
Both act as a flippase for the phospholipid phosphatidylcho-
line. The third important canalicular ABC-transporter is
multidrug resistance-related protein 2 (MRP2) (ABCC2,
cMoat), which is responsible for biliary secretion of organic
anions and glutathione conjugates [174].
The bile acid transporter BSEP has been identified as one
of the major Lith genes involved in gallstone formation in
mice [175] (see below). In mice, the protein may be
responsible for transport of the more hydrophobic bile acids.
In Bsep / mice [176], biliary bile salt output was reduced
to 30% and plasma and hepatic bile acid concentrations
were increased. In contrast, the concentration and output of
both phospholipids and cholesterol in bile were both
increased. The pattern of biliary bile salts in the Bsep
knockout mice was shifted to more hydrophilic species. In
addition, tetrahydroxylated bile acids were present in bile of
knockout mice, which were not found in bile of wild-type
mice. To explain the unexpected increase in biliary lipid
secretion in Bsep / mice, Wang et al. [176] postulated that
accumulation of hepatic bile acids resulting from the
absence of Bsep would inhibit bile acid synthesis which
could lead to the accumulation of cholesterol in the liver.
This in turn may stimulate biliary secretion of cholesterol.
Expression levels of MDR2 were, however, not reported
and up-regulation of this protein by the increased intra-
hepatic bile acids [177] seems to be a more likely explan-
ation. In contrast to mice, the homozygous defect of BSEP
in humans leads to the complete block of bile salt secretion
and severe cholestasis [178]. BSEP is obviously present on
the list of human candidate LITH genes but the results of the
presented animal studies do not necessarily reflect the
human situation.
Disruption of the Mdr2 (Abcb4) gene in mice results in
the absence of phospholipids into bile. In addition, biliary
cholesterol secretion is also very low [179] but bile acid
secretion remains unaltered. The expression and activity of
MDR2 can be regulated by bile salts [177,180]. In addition,
the expression of MDR2 is up-regulated by HMG-CoA
reductase inhibitors [181], fibrates, which are ligands of the
nuclear receptor peroxisome proliferator activating receptor
(PPAR) [182,183], and by peroxisome proliferators in gen-
eral [184].
The molecular mechanism by which cholesterol is
secreted into bile is still an enigma. It has long been thought
that the sterol simply follows phospholipids and that trans-
port is not protein mediated. The coupling between phos-
pholipid and cholesterol is, however, certainly not absolute.
For instance, dietary supplementation with the plant sterol
diosgenin induces a 5- to 7-fold increase in biliary choles-
terol secretion [185–187] and in mice, even a higher up-
regulation of 15-fold has been reported [134]. Since the lipid
composition of the canalicular membrane remains unaltered
under these conditions, increased activity of an as yet not
identified protein factor must be involved. Good candidates
for such an activity are the ABC halftransporters ABCG5
and ABCG8. Patients with sitosterolemia were shown to
have mutations in these genes and seem to have impaired
biliary sterol secretion [93–95]. It can, however, not be
excluded that this effect is secondary to the disturbed
handling of plant sterols in these patients. Mouse models
for these genes allowing rigorous testing are not yet avail-
able.
3.10. Regulatory genes
SREBPs are transcription factors activating genes in-
volved in cholesterol and fatty acid synthesis. Three iso-
forms of SREBPs have been identified. SREBP1a and
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SREBP1c are transcribed from a single gene and only differ
in the N-terminal sequence, whereas SREBP2 is transcribed
from a second gene. In most cell culture systems, SREBP1a
and SREBP2 are the predominantly expressed isoforms,
whereas in the liver and other organs, SREBP1c and
SREBP2 are most highly expressed. When cells are
depleted of sterols, the NH2-terminal part of the full-length
membrane-bound form of each SREBP is cleaved and
released from the membrane in two steps [188–190]. Each
SREBP can act independently on the same genes [188,191]
but the three isoforms have different target gene specific-
ities. All three isoforms tend to stimulate the expression of
multiple genes involved in both cholesterol and fatty acid
synthesis but the relative degree of stimulation varies and
they have differential effects on cholesterol synthesis as
opposed to fatty acid synthesis.
The generation of Srebp1 knockout mice resulted in a
high rate of embryonic lethality. The mice that survived
showed decreased hepatic fatty acid synthesis and the
mRNA levels of these genes tended to be decreased. In
contrast, the mRNA levels of genes of cholesterol synthesis
were increased due to a compensatory activation of
SREBP2. Srebp2 knockout mice were not viable at all [192].
Mice overexpressing a dominant-positive truncated form
of Srebp1a [193] developed fatty livers which was accom-
panied by massive increases in mRNA levels of cholesterol-
synthesizing and fatty acid-synthesizing enzymes and of the
LDL receptor; however, the plasma lipid levels were not
changed in these animals. In Srebp1c transgenic mice, the
liver was not enlarged and only a modest triglyceride accu-
mulation was observed and similarly, the mRNAs encoding
the fatty acid-synthesizing enzymes were only modestly
increased. The mRNAs encoding cholesterol biosynthetic
pathway enzymes were unchanged [192]. Like overexpres-
sion of Srebp1a, overexpression of Srebp2 induced an
enormous increase in the expression of genes in the pathways
of cholesterol and fatty acid biosynthesis and increased
cholesterol (ester) and triglyceride levels in the liver. The
ratio of cholesterol synthesis/fatty acid biosynthesis, how-
ever, was much higher than in Srebp1a-overexpressing mice
[194]. From these animal models, it seemed that SREBP2 is
more effective than SREBP1a in increasing the amount of
mRNAs of genes in cholesterol synthesis, whereas SREBP1a
is more effective in activation of fatty acid synthesis.
SREBP1c is the least effective of all three in both pathways.
In none of the abovementioned SREBP models, however,
biliary cholesterol or gallstone formation was investigated.
The LXR subfamily of nuclear receptors consists of two
members: LXRa (NR1H3) and LXRh (NR1H2). Both have
a different expression pattern. Whereas LXRh is ubiqui-
tously expressed, LXRa is most highly expressed in the
liver and intestinal tract which are the tissues most involved
in cholesterol metabolism. Both receptors form hetero-
dimers with another nuclear receptor, the retinoic X receptor
RXR, which is activated by 9-cis-retinoic acid. LXR ligands
identified thus far are the oxysterols 22R-hydroxycholes-
terol (adrenal glands), 24S-hydroxycholesterol (brain) and
24S,25-epoxycholesterol (liver) [87] and the recently iden-
tified ligand 27-hydroxycholesterol (human macrophages)
which is a product of CYP27 action [76,195–197]. Direct
target genes of LXRa have proven to be CYP7A1 [49,196],
SREBP1c [198,199], ABCA1 [91,200], ABCG1 [201],
ABCG5/G8 [93], CETP [202], ApoE [203], and ABCG4
[204]. LXRa binding to the CYP7A1 promoter increases
the transcription and activity of CYP7A1 in mice leading
to the conversion of cholesterol into bile acids. Lxra /
mice fail to up-regulate CYP7A1 expression on a high-
cholesterol diet and accumulate cholesterol in the liver [49].
Lxrb / mice in contrast are resistant to increased dietary
cholesterol and do not develop fatty livers [205]. In both
types of knockout mice, biliary lipids or gallstone formation
was not investigated. By regulating the transcriptional
activity of key target genes involved in cholesterol catabo-
lism, storage, absorption and transport, LXRa seems to be
the bodies’ key sensing molecule for maintaining choles-
terol homeostasis.
The farnesoid X receptor (FXR, NR1H4) was originally
found to be activated by high concentrations of farnesol
[206]. Recently, it was shown that a number of bile acids,
including chenodeoxycholic, cholic, deoxycholic and lith-
ocholic acids bound and activated FXR in cultured cells
[207–209]. Identified target genes of FXR include genes
involved in bile acid transport and biosynthesis [210,211]
that were previously known to be regulated by bile acids:
CYP7A1 and CYP8B1 [212], the basolateral sodium taur-
ocholate cotransporter protein NTCP [213], the hepatic
canalicular bile salt transporter BSEP [214,215], the ileal
bile acid binding protein I-BABP [207,216,217], the small
heterodimeric partner (SHP) [65,66] and phospholipid
transfer protein (PLTP) [218,219]. Mice with a targeted
disruption of the Fxr gene [220] failed to correctly control
bile acid biosynthesis and excretion. In a situation of an
increased bile acid concentration, FXR is activated and
promotes the transcription of SHP. Increased levels of SHP
protein inactivate the liver receptor homolog 1 (LRH1) by
forming a complex which leads to an inhibition of tran-
scription of CYP7A1 and the other target genes [65,66].
This mechanism has been shown for the target genes
CYP7A1 and NTCP [65,66,221]. However, direct regula-
tion of FXR by binding of FXR to the BSEP promoter has
also been shown [215].
The liver receptor homologue LRH1 (NR5A2) is a mono-
meric orphan receptor and is the mammalian homolog of the
Drosophila fushi tarazu F1 receptor gene [63,222]. It is
expressed in liver, pancreas, intestine, and ovary and binds
to DNA as monomer. LHR-1 is believed to serve as a tissue-
specific competence factor for bile acid synthesis. No ligands
have been reported for LRH1 but target genes include: a-
fetoprotein [63], SHP [223], CETP [202], CYP7A1 [222],
and CYP8B1 [224].
SHP, the small heterodimeric partner (NR0B2) hetero-
dimerizes with several nuclear receptors [225]. It has a
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ligand-binding domain but it lacks a DNA binding domain.
It is expressed in the liver, intestine, heart, pancreas and
adrenal glands [225], and has been shown to be a potent
repressor of LRH1 and its target genes. SHP is suggested to
be a constitutive repressor and not to have an endogenous
ligand [65,66,225–228]. Together, SHP and LRH1 seem to
be important factors in the regulation of expression of genes
involved in transport and synthesis of bile acids, thereby
influencing the CSI in bile.
Peroxisome proliferator-activated receptors (PPARs) were
identified as nuclear receptors activated by hypolipidemic
compounds, like fibrates, but fatty acids have been found to
be the natural ligands. Genes involved in fatty acid metabo-
lism, h-oxidation and N-oxidation have been found to be
activated by PPARa (NR1C1) and specific target genes of
PPARa are peroxisomal acyl-CoA oxidase (ACO), CYP4A1
and enoyl-CoA/3-hydroxyacylCoA hydratase/dehydrogen-
ase multifunctional enzyme. Mice with a targeted disruption
of the Ppara gene lacked peroxisome proliferation and lacked
induction of peroxisome proliferator-regulated genes in
response to fibrates [229–231]. In addition, Ppara-null mice
showed increased total and HDL-cholesterol levels [232].
Fibrates are known to lower plasma triglycerides and
cholesterol levels [233]. One of these fibrates, bezafibrate,
altered the bile acid composition in bile, by inducing an
increase in CA and a decrease in CDCA, suggesting the
involvement of PPARa in the expression of CYP8B1.
Hunt et al. [231] showed that CYP8B1 is up-regulated by
PPARa ligands and a concomitant increase in the amount
of CA formed was found. CYP7A1 levels were not
changed in Ppara-null mice. In contrast, administration
of fibrates to humans does reduce CYP7A1 expression,
resulting in an increased risk for gallstone formation
[233–236]. Post et al. [237] recently showed that fibrates
down-regulated the expression of CYP7A1 and CYP27 in
mice and that fecal bile acid secretion was decreased and
fecal cholesterol secretion increased, both being PPARa
dependent.
Numerous functions of the liver are controlled primarily
at the transcriptional level by the actions of a limited number
of hepatocyte-enriched transcription factors which include
the HNF 1a, -1, -3a, -3h, -3g, -4a, and -6. Tcf1 (encoding
for HNF1a) deletion induced enlarged fatty livers and
hypercholesterolemia in mice. In addition, the expression
of genes encoding for hepatic bile salt uptake (NTCP, Oatp1
and Oatp2) were decreased resulting in a defect in bile acid
uptake and increased plasma bile salt levels. Furthermore,
CYP7A1 and HMGR expression levels were elevated
resulting in increased synthesis of bile acids and hepatic
cholesterol, whereas HDL metabolism was impaired. In
addition, FXR expression was down-regulated and the
genes were identified as a direct target of HNF1. The
Tcf1 / mice also showed elevated expression of genes
encoding enzymes involved in the synthesis, catabolism,
and transport of fatty acids and of the peroxisomal h-
oxidation enzymes (CYP4A3, bifunctional enzyme and
thiolase). In contrast, there was a marked reduction of liver
fatty acid-binding protein (l-FABP) expression in the livers
of Tcf1 null mice [238,239].
Although the liver-specific deletion of Hnf3b does not
have large effects on liver gene expression [240], in mice
overexpressing liver-specific Hnf3b, decreased expression
of sinusoidal bile acid uptake transporter NTCP and the
canalicular phospholipid transporter MDR2 was seen, but
the expression of BSEP and MRP2 did not change.
Mice lacking hepatic Hnf4a accumulated lipids in the
liver and serum cholesterol and triglyceride levels were
enormously decreased, whereas serum bile acid concentra-
tions were increased [241]. Unfortunately, biliary lipids
were not measured in this study. HNF4 has been also shown
to regulate the expression of CYP8B1 [242,243], CYP7A1
[244], and CYP27 [245].
3.11. Lith genes
Major indications for the genetic basis for cholesterol
gallstone formation are the numerous inbred mouse strains
with different basal levels of total plasma cholesterol [246]
and differential susceptibility to gallstone formation. Total
cholesterol levels in plasma (mainly HDL) were the highest
in NZB/B1NJ and 129/J strains which had significantly
higher total plasma cholesterol levels than the C3H/HeJ
strain, whereas the lowest levels were found in the SWR/J
strain. The other investigated mouse strains showed inter-
mediate plasma cholesterol levels in the following order:
A/J < BALB/cByJ < C57BL/6J < AKR/J < DBA/2J. When
C57L/J mice were fed a lithogenic diet, 90% of the mice
developed gallstones, whereas gallstones were observed
only in 10% of AKR mice [20,247,248]. The susceptible
C57L/J mice had early cholesterol supersaturation in bile
and larger gallbladders [248]. The resistant AKR mice,
however, developed fatty liver and had higher hepatic
cholesterol levels on basal diet, which were increased on a
lithogenic diet. C57L mice had higher HDL levels than
AKR mice, which decreased on a lithogenic diet. HDL
levels in AKR mice increased on the lithogenic diet. Both
biliary cholesterol and phospholipid secretion rates were
higher in the susceptible C57L mice than in the AKR strain.
On a lithogenic diet, cholesterol and phospholipid secretion
rates increased significantly in both strains, but in AKR
mice, this increase was smaller. These mice had also a
higher bile flow due to an increased bile acid-independent
bile flow. Total bile salt secretion on chow diet was 1.5-fold
higher in C57L mice than AKR mice and remained com-
parable on lithogenic diet. The cholesterol/phospholipid
ratio in bile of AKR mice remained constant on both diets,
whereas in C57L mice, this ratio increased. The cholesterol/
bile acid ratio was also higher in C57L mice on lithogenic
diet and increased only slightly in bile of AKR mice. The
increased cholesterol/phospholipid ratio in C57L induced an
increase in CSI in bile, promoting the formation of gall-
stones in C57L mice. In bile of gallstone patients, also
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higher cholesterol/phospholipid ratios have been reported
[249]. The differences between the inbred mouse strains in
gallstone formation [250] was the reason for Khanuja et al.
[247] to start quantitative trait loci (QTL) analysis to locate
chromosomal regions containing genes involved in the
differences in gallstone susceptibility. In accordance with
gallstone formation being a polygenic disease, multiple QTL
regions have been found when the gallstone-susceptible
C57L/J mice were crossed with the gallstone-resistant
AKR mouse strain [247]. The analysis also revealed that
gallstone formation is a dominant trait. At least two strong
QTLs have been identified, called Lith-1 and -2 [4]. In
addition, several other QTLs were identified in this cross
but were less significant. Several other crosses have been
performed, identifying additional QTLs [251]. A candidate
gene for Lith-1 was later shown to be the bile salt export
pump BsepI [175], whereas Lith-2 was associated withMrp2
[252] and increased bile flow as well as secretion rates of
glutathione and bilirubin conjugates [253]. In C57l mice,
expression of SR-BI and ACAT2 was increased 2.5- and 2-
fold, respectively, whereas it remained unchanged in AKR
mice on the lithogenic diet. HMG-CoA reductase expression
failed to down-regulate on the lithogenic diet in C57L mice.
The lithogenic diet also increased the cholesterol ester
hydrolase mRNA and protein levels in C75L mice, whereas
these remained unchanged in AKR mice.
4. Indirect evidence for genetic background of human
cholesterol gallstones
4.1. Epidemiology of cholesterol gallstones
The highest prevalence of gallstones was reported in
European and particularly Amerindian populations, the low-
est prevalence was found in Africans and intermediate
prevalence rates were observed in the Far East and India
[254,255]. Based on 22 sonographic studies published in the
years 1979–1995, Kratzer et al. [254] estimated the mean
prevalence rate of cholecystolithiasis in Europe to be 10–
12%. A similar value (15.7%) was calculated earlier by Brett
and Barker [255] in their critical overview of a series of
autopsy studies. Surprisingly, few data have been reported for
North American populations, whereas multiple studies were
conducted in Latin America [256–261]. In North America,
the detailed prevalence data are available only for Hispanics
[262,263] and Native Americans [264–267], whereas only a
limited number of studies have been performed in North
American Caucasians [268–270]. The data obtained by
Bortnichak et al. [269] from 5209 subjects involved in the
Framingham Heart Study are of particular interest because
the association between cholesterol gallstones and increased
risk of atherosclerosis in male but not female gallstone
patients was reported for the first time in this study.
Native Americans have the highest prevalence of chol-
elithiasis: 48% overall prevalence was found in Pima
Indians [264] and somewhat lower prevalence rates were
found in Chileans [257] and in other Native American
populations [265,271]. In contrast, the overall prevalence
in other American populations was around (non-Cauca-
sians) or below (Caucasians) 20%.
The striking differences in prevalence rates of gallstones
between different populations within the same American
continents suggest a role of the genetic background in the
etiology of the disease. However, most of the differences
between epidemiological data may also be (partially) ex-
plained by environmental factors or by factors relating to
study design (autopsy vs. sonography or cholecystography,
prospective vs. retrospective, gender and age distribution,
and response rate).
To check the influence of the genetic background more
rigorously, prevalence of the disease in migrants coming
from the region with a certain prevalence of gallstones
integrated into a new environment with a different preva-
lence of gallstones should be compared with the prevalence
in the genetically homogenous acceptor population. Un-
fortunately, rapid loss of the original genetic background
within a few generations makes such studies difficult. In a
recent cross-sectional population study of Brasca et al.
[261], Italian and Spanish descendants fully integrated into
the US society but having all four grandparents of the same
Italian or Spanish origin presented higher prevalence rates
for all age groups than those reported in Italy and Spain.
Interestingly, the difference was significantly higher among
the young subjects of both sexes, lower in the intermediate
age group and almost no difference was found in subjects
older than 60 years. These findings, in accordance with the
data obtained from Pima Indians and other high-risk pop-
ulations, clearly indicate the importance of genetic disposi-
tion for early manifestation of the disease.
4.2. Family and twin studies
Surprisingly few genetic studies on gallstone disease in
humans have been published until now. In the first study
conducted by Huddy in 1925 [272], the incidence of
cholelithiasis in family members of 57 non-related affected
individuals was 42% as compared with less than 16% in
families of 100 controls with no history of ‘‘indigestion’’.
Ko¨rner [273] found the frequency of gallstones in 74
families of gallstone patients to be five times higher than
in families of non-affected controls. In a study of Littler and
Ellis [274], 20.8% of 100 patients with gallstones gave a
positive family history. Jackson and Gay [275] studied first-
degree relatives from 100 patients with gallbladder disease.
Definite or suggestive evidence of gallbladder disease was
found in 72% of the first-degree relatives. Definite gall-
bladder disease at least in one parent was found in 33% and
only in two cases neither parent had gallbladder disease. A
different approach was chosen in a study of van der Linden
and Lindelo¨f [276] who compared the occurrence of gall-
stone disease in patient’s siblings and husbands or wives.
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Gallstone disease was found to occur more often among the
siblings of gallstone disease patients. The incidence of
gallstones in wives of the gallstone patients and wives of
their healthy brothers did not differ [277], indicating genetic
background of the disease. In their third study, van der
Linden and Simondson [278–280] focused on the incidence
of gallstones among the parents of young ( < 22 years)
gallstone patients. A group of 37 patients was compared
with two age- and sex-matched control groups: 37 ran-
domly chosen healthy individuals (group I) and 37 patients
with normal cholecystography performed because of
uncharacteristic abdominal complaints (group II). Either
parent was affected in 20 of 37 patients but only in 7 of
37 and 14 of 37 subjects from control groups I and II,
respectively. Neither parent had gallstones in 12, 29 and 23
subjects from patient group, control group I and control
group II, respectively. Lithogenicity of duodenal bile was
investigated in older and younger sisters of 11 gallstone
females (mean age 21.1 years) by Danzinger et al. [281].
Four from eight older sisters (mean age 29.4 years), 1 from
10 age-matched controls and 1 from 10 younger sisters
(mean age 20.3 years) had lithogenic bile. Gilat et al. [279]
studied, in a prospective manner, the frequency of gall-
stones in 171 first-degree relatives of patients with proven
gallstones compared with 200 matched controls. All sub-
jects were studied by oral cholecystography, and their
height, weight, blood glucose, cholesterol, and other param-
eters were measured. Gallstones were found in 20.5% of the
first-degree relatives and in 9.0% of the control group. In
the most recent study, Sarin et al. [280] evaluated 330 first-
degree relatives of gallstone-positive index patients using
ultrasonography. Stones were found in 15.5% of first-
degree relatives compared to only 3.6% of matched controls
and the risk was higher for female relatives. Despite the
different design of the presented studies, their results uni-
vocally indicate the importance of genetic background of
cholelithiasis.
More evidence supporting the role of inherited disposi-
tion to gallstones comes from the twin studies. A definite
preponderance of concordant cases of gallstones among the
uniovular pairs (7 of 18) compared with the biovular pairs of
twins of the same sex (3 of 37) was found in a catamnestic
investigation of 101 Danish twins with gallstones performed
by Harvald and Hauge [282]. From two unselected series of
twins investigated by Doig [283], cholelithiasis was present
in one or both of 133 pairs. Concordance was demonstrated
in 9 of 23 identical pairs but only in 4 of 42 fraternal pairs of
the same sex. Unfortunately, in the series of the selected
pairs that underwent both clinical and laboratory investiga-
tion (see also Doig and Pitman [284]), cholelithiasis
occurred only in four monozygous and six dizygous cou-
ples. Concordance was seen in two monozygous and one
dizygous pairs. An outstanding study of biliary lipid com-
position in monozygotic and dizygotic pairs of twins was
conducted by Antero Kesaniemi et al. [285]. The relative
contribution of genetic factors to biliary and serum lipid
composition, including cholesterol precursors, squalene and
methylated sterols which reflect the activity of cholesterol
synthesis was studied in 17 monozygotic and 18 dizygotic
middle-aged male pairs of twins. Gallstones were found in
seven monozygotic (three concordant pairs) and three dizy-
gotic subjects (all discordant pairs). The pairwise correla-
tions of all measured parameters tended to be higher in the
monozygotic than in the dizygotic pairs, suggesting a
significant genetic control. However, no target genes were
identified.
5. Direct proofs of the role of genes in human gallstone
disease
5.1. Single gene defects
The first evidence that human gallstone disease might be
caused by a single gene defect came recently from the
studies of Rosmorduc et al. [1] and Jacquemin et al. [286].
In the first study, six symptomatic adult patients with a
peculiar form of biliary gallstone disease characterized by
intrahepatic sludge, gallbladder cholesterol gallstones asso-
ciated with mild chronic cholestasis and recurrence of
symptoms after cholecystectomy were studied. In two of
them, hepatic bile analysis showed supersaturation with
cholesterol together with low phospholipid concentration.
This finding led to the hypothesis that a defect in the MDR3
gene could constitute the genetic basis for this highly
symptomatic and recurrent form of gallstone disease.
Indeed, a heterozygous nonsense mutation in two patients,
a homozygous missense mutation in three other patients,
and a heterozygous missense mutation in one patient were
detected. None of these mutations was reported previously
in patients with progressive familiar intrahepatic cholestasis
type 3 caused by homozygous mutations of MDR3 gene
leading to complete absence of MDR3 protein and secretion
of phospholipids into bile [286,287]. None of the studied
patients manifested any sign of liver disease in childhood.
Jacquemin et al. [286] investigated 31 patients with choles-
tatic liver disease possessing the features of progressive
familiar intrahepatic cholestasis type 3. Mutations of MDR3
were detected in 17 patients. Gallbladder stones were found
in four children and two parents. Both studies showed that
defects of MDR3 might play a more general role in liver
diseases such as liver cirrhosis, cholesterol gallstones and
familial cholestasis of pregnancy (see also Refs. [288,289];
however, making direct links between liver diseases with
common and frequent phenotype and mutations in less
conserved regions of the coding sequence that do not affect
protein expression without functional studies and further
analysis of the genetic background might be premature
[290].
A new link between another single gene defect, the
CYP7A1 deficiency, and premature cholesterol gallstones
associated with hypercholesterolemia resistant to HMG-
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CoA inhibitors in two male homoyzgotes, has recently been
reported in an elegant study of Pullinger et al. [3].
5.2. Multiple gene defects and polymorphism studies
Direct evidence for the role of genes in human gallstones
should come from multiple gene defects and polymorphisms
associated with gallstones. No multiple gene mutation has
been reported in a gallstone patient to our knowledge. In
contrast, putative associations between a series human gene
polymorphisms and gallstones have been published. Some
of these studies were already discussed in the above
sections. A brief overview of the polymorphism studies will
be presented in this section.
ApoE polymorphism is the most extensively studied
polymorphism in gallstone patients. Controversial data pub-
lished on the protective role of the epsilon4 allele against
gallstones have already been mentioned [153–156]. In con-
trast, the epsilon2 allele seems to act as a protecting factor
against gallstones in the middle age according to Niemi et al.
[291] whose data are further supported by the earlier work of
Kesaniemi et al. [157]. These authors demonstrated that the
percentage of dietary cholesterol absorption decreased in the
order of ApoE isoforms E4>E3>E2, and also showed that the
fecal excretion of cholesterol tended to be higher in individ-
uals having the ApoE2 phenotype compared with E3 or E4
individuals [158].
In a study of polymorphisms at the ApoB, ApoAI, and
cholesteryl ester transfer protein gene loci in patients with
gallbladder disease conducted by Juvonen et al. [292],
CETP polymorphism associated with another HDL low-
ering factor might be associated with cholesterol gallstone
disease. A link between the X+ allele of the ApoB gene and
the increased risk of cholesterol gallstone disease was
proposed by Han et al. [293].
Besides the genes involved in biliary secretion of choles-
terol, a set of genes controlling emptying of the gallbladder
might participate in the etiology of gallstone disease. A
search for mutations and/or polymorphisms in the chole-
cystokinin receptor gene in gallstone patients performed by
Nardone et al. [294] was, however, unsuccessful.
In contrast to the previous section, no genetic or bio-
chemically defined risk factor(s) associated with the strong
increase of the risk of gallstone disease has been disclosed
in any of the studies presented in this section.
5.3. Genetic diseases associated with cholesterol gallstones
Genetic diseases associated with cholesterol gallstones
caused by defects of the genes that are not directly involved
in biliary lipid secretion will be listed in this section.
Increased incidence of radiolucent gallstones has been
observed in patients with cystic fibrosis [295–297], DS
[298] and Gaucher disease [299].
Patients with cystic fibrosis now commonly survive into
adulthood and are at high risk for the development of
gallstones. The diagnosis may be obscured by other com-
mon gastrointestinal complications of cystic fibrosis. Radio-
lucent gallstones found on cholecystography were thought
to be cholesterol gallstones. This hypothesis was further
supported by changes of biliary lipid composition found by
Roy et al. [300]. In this study, in 14 patients with cystic
fibrosis who had stopped taking pancreatic enzymes for 1
week, the molar percentage of cholesterol and CSI were
comparable to values of the cholelithiasis group and almost
twice higher than those of controls. In 12 patients with
cystic fibrosis taking pancreatic enzymes, the molar per-
centage of cholesterol and saturation index did not differ
from those of controls. The findings of Roy et al. [300] were
not confirmed in a later study by Angelico et al. [301] who
found non-significant changes in CSI between patients with
cystic fibrosis with (1.21F 0.28, n = 10) and without
(0.99F 0.54, n = 7) gallstones. Gallstones available from
two patients who died of severe bronchopneumopathy
contained mainly calcium bilirubinate and protein while
their cholesterol content was only 44% and 28% of dry
weight. Interestingly, samples of duodenal bile from all 17
patients were checked for microlithiasis and the findings
were negative. The authors came to the conclusion that
radiolucent gallstones of patients with cystic fibrosis are not
of the conventional cholesterol type.
The link between increased risk of gallstones and DS was
suggested by Elias Pollina et al. [302] who analyzed 56
cases of cholelithiasis in patients aged 2 months to 15 years.
A combination of cholelithiasis with DS was present in four
cases from the studied series. Several cases of gallstones in
infants with DS were reported in two later studies of
Aughton et al. [303] and Aynaci et al. [304]. A systematic
prospective study was carried out recently [298]. Of the 126
patients with DS who underwent abdominal ultrasound
examination, 6 (4.7%) were found to have cholelithiasis.
In contrast, among the 577 age-matched controls, only 1
(0.2%) 7-year-old girl had gallstones. All seven children
with cholelithiasis were born at term, were asymptomatic,
and did not have identifiable risk factors for gallstones. In
the six children with DS and cholelithiasis, abdominal X-ray
did not show radiopaque gallstones indicating a high
amount of cholesterol in the stones. However, to our knowl-
edge, no data on the composition of bile or gallstones from
patients with DS have been published.
The fact that gallstones are often found in patients with
Gaucher disease was based on clinical experience but little
epidemiological data are available. Perez-Calvo et al. [299]
published recently the results of a national study of co-
morbidity with other common diseases such as dementia,
Parkinson disease, ischemic stroke, ischemic heart disease,
non-rheumatic valvular disease, hematological and non-
hematological malignancies, pulmonary fibrosis, tuberculo-
sis, schizophrenia and gallstones conducted in 67 patients
with Gaucher disease, 132 nonaffected heterozygous car-
riers and 59 healthy relatives. Patients with Gaucher
appeared to have the greatest risk of developing gallstone
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disease. This increased risk was particularly high among
female patients and could not be explained in terms of
differences in age. Patients with Gaucher disease have very
low HDL cholesterol; the underlying mechanism is not
known but increased reverse cholesterol transport leading
to increased biliary secretion of cholesterol has been sug-
gested.
6. Conclusions and future prospects
The etiology of cholesterol gallstone disease is clearly
multifactorial. This is probably the reason that apart from a
few (very rare) exceptions, the genetic background of this
extremely common disease has not been elucidated. In this
overview, we show that secretion of the main biliary
components cholesterol phospholipid and bile salts are all
subject to complex regulatory mechanisms and are formed
by complex metabolic pathways. Relatively small changes
in secretion rates of one or more of these biliary components
are enough to induce gallstone formation. Therefore, subtle
changes in a number of the steps caused by polymorphisms
in the responsible genes may well underlie formation of
gallstones. Identification of these polymorphisms is the
challenge for the near future.
References
[1] O. Rosmorduc, B. Hermelin, R. Poupon, Gastroenterology 120
(2001) 1459–1467.
[2] E. Jacquemin, Semin. Liver Dis. 21 (2001) 551–562.
[3] C.R. Pullinger, C. Eng, G. Salen, S. Shefer, A.K. Batta, S.K.
Erickson, A. Verhagen, C.R. Rivera, S.J. Mulvihill, M.J. Malloy, J.P.
Kane, J. Clin. Invest. 110 (2002) 109–117.
[4] B. Paigen, N.J. Schork, K.L. Svenson, Y.C. Cheah, J.L. Mu, F.
Lammert, D.Q. Wang, G. Bouchard, M.C. Carey, Physiol. Ge-
nomics 4 (2000) 59–65.
[5] F. Lammert, M.C. Carey, B. Paigen, Gastroenterology 120 (2001)
221–238.
[6] M. Jirsa, A.K. Groen, Front. Biosci. 6 (2001) E154–E167.
[7] K. Empen, K. Lange, E.F. Stange, J. Scheibner, Am. J. Physiol. 272
(1997) G367–G373.
[8] J. Scheibner, M. Fuchs, E. Hormann, G. Tauber, E.F. Stange, J. Lipid
Res. 35 (1994) 690–697.
[9] S.J. Robins, J.M. Fasulo, P.D. Lessard, G.M. Patton, Biochem. J.
289 (1993) 41–44.
[10] C.C. Schwartz, L.G. Halloran, Z.R. Vlahcevic, D.H. Gregory, L.
Swell, Science 200 (1978) 62–64.
[11] A.K. Groen, V.W. Bloks, R.H. Bandsma, R. Ottenhoff, G. Chimini,
F. Kuipers, J. Clin. Invest. 108 (2001) 843–850.
[12] R.H. Bandsma, F. Kuipers, R.J. Vonk, R. Boverhof, P.J. Sauer, G.T.
Nagel, H. Elzinga, R.A. Neese, M.K. Hellerstein, F. Stellaard, Bio-
chim. Biophys. Acta 1483 (2000) 343–351.
[13] J. Scheibner, M. Fuchs, M. Schiemann, E.F. Stange, Hepatology 21
(1995) 529–538.
[14] J.L. Goldstein, M.S. Brown, Nature 343 (1990) 425–430.
[15] Y. Sakakura, H. Shimano, H. Sone, A. Takahashi, N. Inoue, H.
Toyoshima, S. Suzuki, N. Yamada, K. Inoue, Biochem. Biophys.
Res. Commun. 286 (2001) 176–183.
[16] M.D. Siperstein, V.M. Fagan, J. Biol. Chem. 241 (1966) 602–609.
[17] K.D. Clinkenbeard, W.D. Reed, R.A. Mooney, M.D. Lane, J. Biol.
Chem. 250 (1975) 3108–3116.
[18] C.F. Clarke, R.D. Tanaka, K. Svenson, M. Wamsley, A.M. Edwards,
P.A. Edwards, Mol. Cell. Biol. 7 (1987) 3138–3146.
[19] I. Shechter, E. Klinger, M.L. Rucker, R.G. Engstrom, J.A. Spirito,
M.A. Islam, B.R. Boettcher, D.B. Weinstein, J. Biol. Chem. 267
(1992) 8628–8635.
[20] M. Fuchs, B. Ivandic, O. Muller, C. Schalla, J. Scheibner, P. Bartsch,
E.F. Stange, Hepatology 33 (2001) 1451–1459.
[21] R.L. Ginsberg, W.C. Duane, E.V. Flock, J. Lab. Clin. Med. 89
(1977) 928–936.
[22] J. Ahlberg, B. Angelin, K. Einarsson, J. Lipid Res. 22 (1981)
410–422.
[23] P.N. Maton, A. Reuben, R.H. Dowling, Clin. Sci. (Lond.) 62 (1982)
515–519.
[24] E. Reihner, B. Angelin, I. Bjorkhem, K. Einarsson, J. Lipid Res. 32
(1991) 469–475.
[25] T.Y. Chang, C.C. Chang, D. Cheng, Annu. Rev. Biochem. 66 (1997)
613–638.
[26] D.S. Goodman, Physiol. Rev. 45 (1965) 747–839.
[27] C.C. Chang, H.Y. Huh, K.M. Cadigan, T.Y. Chang, J. Biol. Chem.
268 (1993) 20747–20755.
[28] P.J. Uelmen, K. Oka, M. Sullivan, C.C. Chang, T.Y. Chang, L. Chan,
J. Biol. Chem. 270 (1995) 26192–26201.
[29] V. Meiner, C. Tam, M.D. Gunn, L.M. Dong, K.H. Weisgraber, S.
Novak, H.M. Myers, S.K. Erickson, R.V. Farese Jr., J. Lipid Res. 38
(1997) 1928–1933.
[30] V.L. Meiner, S. Cases, H.M. Myers, E.R. Sande, S. Bellosta, M.
Schambelan, R.E. Pitas, J. McGuire, J. Herz, R.V. Farese Jr., Proc.
Natl. Acad. Sci. U. S. A. 93 (1996) 14041–14046.
[31] R.A. Anderson, C. Joyce, M. Davis, J.W. Reagan, M. Clark, G.S.
Shelness, L.L. Rudel, J. Biol. Chem. 273 (1998) 26747–26754.
[32] S. Cases, S. Novak, Y.W. Zheng, H.M. Myers, S.R. Lear, E. Sande,
C.B. Welch, A.J. Lusis, T.A. Spencer, B.R. Krause, S.K. Erickson,
R.V. Farese Jr., J. Biol. Chem. 273 (1998) 26755–26764.
[33] P. Oelkers, A. Behari, D. Cromley, J.T. Billheimer, S.L. Sturley, J.
Biol. Chem. 273 (1998) 26765–26771.
[34] K.K. Buhman, M. Accad, S. Novak, R.S. Choi, J.S. Wong, R.L.
Hamilton, S. Turley, R.V. Farese, Nat. Med. 6 (2000) 1341–1347.
[35] J.L. Smith, I.R. Hardie, S.P. Pillay, J. de Jersey, J. Lipid Res. 31
(1990) 1993–2000.
[36] C.C. Chang, N. Sakashita, K. Ornvold, O. Lee, E.T. Chang, R.
Dong, S. Lin, C.Y. Lee, S.C. Strom, R. Kashyap, J.J. Fung, R.V.
Farese Jr., J.F. Patoiseau, A. Delhon, T.Y. Chang, J. Biol. Chem. 275
(2000) 28083–28092.
[37] S. Ghosh, R. Natarajan, W.M. Pandak, P.B. Hylemon, W.M. Grogan,
Am. J. Physiol. 274 (1998) G662–G668.
[38] Z.R. Vlahcevic, 3rd ed., in: D. Zakim, T. Boyer (Eds.), Hepatology:
Textbook of Liver Diseases, vol. 1, W.B. Saunders, Philadelphia,
1996, pp. 376–417.
[39] Z.R. Vlahcevic, W.M. Pandak, R.T. Stravitz, Gastroenterol. Clin.
North Am. 28 (1999) 1–25.
[40] H.M. Princen, P. Meijer, B.G. Wolthers, R.J. Vonk, F. Kuipers, Bio-
chem. J. 275 (1991) 501–505.
[41] R.T. Stravitz, Z.R. Vlahcevic, T.L. Russell, M.L. Heizer, N.G.
Avadhani, P.B. Hylemon, J. Steroid Biochem. Mol. Biol. 57 (1996)
337–347.
[42] Z.R. Vlahcevic, R.T. Stravitz, D.M. Heuman, P.B. Hylemon, W.M.
Pandak, Gastroenterology 113 (1997) 1949–1957.
[43] W.C. Duane, J. Lipid Res. 38 (1997) 183–188.
[44] M. Goldman, Z.R. Vlahcevic, C.C. Schwartz, J. Gustafsson, L.
Swell, Hepatology 2 (1982) 59–66.
[45] L. Swell, J. Gustafsson, C.C. Schwartz, L.G. Halloran, H. Daniels-
son, Z.R. Vlahcevic, J. Lipid Res. 21 (1980) 455–466.
[46] S.D. Turley, D.K. Spady, J.M. Dietschy, Hepatology 25 (1997)
797–803.
[47] W.M. Pandak, Y.C. Li, J.Y. Chiang, E.J. Studer, E.C. Gurley, D.M.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–1914
Heuman, Z.R. Vlahcevic, P.B. Hylemon, J. Biol. Chem. 266 (1991)
3416–3421.
[48] S.D. Turley, M. Schwarz, D.K. Spady, J.M. Dietschy, Hepatology 28
(1998) 1088–1094.
[49] D.J. Peet, S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E.
Hammer, D.J. Mangelsdorf, Cell 93 (1998) 693–704.
[50] G. Xu, G. Salen, S. Shefer, G.C. Ness, L.B. Nguyen, G.S. Tint, T.S.
Parker, J. Roberts, A.K. Batta, T.S. Chen, Z. Zhao, X. Kong, Hep-
atology 24 (1996) 882–887.
[51] J.D. Horton, J.A. Cuthbert, D.K. Spady, J. Biol. Chem. 270 (1995)
5381–5387.
[52] L. Rudel, C. Deckelman, M. Wilson, M. Scobey, R. Anderson, J.
Clin. Invest. 93 (1994) 2463–2472.
[53] P. Couture, J.D. Otvos, L.A. Cupples, P.W. Wilson, E.J. Schaefer,
J.M. Ordovas, J. Lipid Res. 40 (1999) 1883–1889.
[54] J.Y. Chiang, R. Kimmel, D. Stroup, Gene 262 (2001) 257–265.
[55] M. Schwarz, D.W. Russell, J.M. Dietschy, S.D. Turley, J. Lipid Res.
39 (1998) 1833–1843.
[56] D.K. Spady, J.A. Cuthbert, M.N. Willard, R.S. Meidell, J. Clin.
Invest. 96 (1995) 700–709.
[57] W.M. Pandak, C. Schwarz, P.B. Hylemon, D. Mallonee, K. Valerie,
D.M. Heuman, R.A. Fisher, K. Redford, Z.R. Vlahcevic, Am. J.
Physiol.: Gastrointest. Liver Physiol. 281 (2001) G878–G889.
[58] L.B. Agellon, V.A. Drover, S.K. Cheema, G.F. Gbaguidi, A. Walsh,
J. Biol. Chem. 277 (2002) 20131–20134.
[59] J.Y. Chiang, W.F. Miller, G.M. Lin, J. Biol. Chem. 265 (1990)
3889–3897.
[60] M. Crestani, W.G. Karam, J.Y. Chiang, Biochem. Biophys. Res.
Commun. 198 (1994) 546–553.
[61] W.M. Pandak, Z.R. Vlahcevic, D.M. Heuman, K.S. Redford, J.Y.
Chiang, P.B. Hylemon, Hepatology 19 (1994) 941–947.
[62] M. Crestani, A. Sadeghpour, D. Stroup, G. Galli, J.Y. Chiang, J.
Lipid Res. 39 (1998) 2192–2200.
[63] L. Galarneau, J.F. Pare, D. Allard, D. Hamel, L. Levesque, J.D.
Tugwood, S. Green, L. Belanger, Mol. Cell. Biol. 16 (1996)
3853–3865.
[64] W. Chen, E. Owsley, Y. Yang, D. Stroup, J.Y. Chiang, J. Lipid Res.
42 (2001) 1402–1412.
[65] T.T. Lu, M. Makishima, J.J. Repa, K. Schoonjans, T.A. Kerr, J.
Auwerx, D.J. Mangelsdorf, Mol. Cell 6 (2000) 507–515.
[66] B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee,
L.B. Moore, C. Galardi, J.G. Wilson, M.C. Lewis, M.E. Roth, P.R.
Maloney, T.M. Willson, S.A. Kliewer, Mol. Cell 6 (2000) 517–526.
[67] S. Gupta, R.T. Stravitz, P. Dent, P.B. Hylemon, J. Biol. Chem. 276
(2001) 15816–15822.
[68] J.J. Cali, D.W. Russell, J. Biol. Chem. 266 (1991) 7774–7778.
[69] M. Schwarz, E.G. Lund, R. Lathe, I. Bjorkhem, D.W. Russell, J.
Biol. Chem. 272 (1997) 23995–24001.
[70] A. Babiker, U. Diczfalusy, Biochim. Biophys. Acta 1392 (1998)
333–339.
[71] A. Babiker, O. Andersson, E. Lund, R.J. Xiu, S. Deeb, A. Reshef, E.
Leitersdorf, U. Diczfalusy, I. Bjorkhem, J. Biol. Chem. 272 (1997)
26253–26261.
[72] I. Bjorkhem, O. Andersson, U. Diczfalusy, B. Sevastik, R.J. Xiu,
C. Duan, E. Lund, Proc. Natl. Acad. Sci. U. S. A. 91 (1994)
8592–8596.
[73] E. Lund, O. Andersson, J. Zhang, A. Babiker, G. Ahlborg, U.
Diczfalusy, K. Einarsson, J. Sjovall, I. Bjorkhem, Arterioscler.
Thromb. Vasc. Biol. 16 (1996) 208–212.
[74] M. Axelson, O. Larsson, J. Zhang, J. Shoda, J. Sjovall, J. Lipid Res.
36 (1995) 290–298.
[75] C. Bhuvaneswaran, S. Synouri-Vrettakou, K.A. Mitropoulos, Bio-
chem. Pharmacol. 53 (1997) 27–34.
[76] X. Fu, J.G. Menke, Y. Chen, G. Zhou, K.L. MacNaul, S.D. Wright,
C.P. Sparrow, E.G. Lund, J. Biol. Chem. 276 (2001) 38378–38387.
[77] J. Twisk, E.C. de Wit, H.M. Princen, Biochem. J. 305 (1995)
505–511.
[78] Z. Araya, H. Sjoberg, K. Wikvall, Biochem. Biophys. Res. Com-
mun. 216 (1995) 868–873.
[79] G. Salen, S. Shefer, F.W. Cheng, B. Dayal, A.K. Batta, G.S. Tint, J.
Clin. Invest. 63 (1979) 38–44.
[80] H. Rosen, A. Reshef, N. Maeda, A. Lippoldt, S. Shpizen, L. Triger,
G. Eggertsen, I. Bjorkhem, E. Leitersdorf, J. Biol. Chem. 273 (1998)
14805–14812.
[81] J.J. Repa, E.G. Lund, J.D. Horton, E. Leitersdorf, D.W. Russell, J.M.
Dietschy, S.D. Turley, J. Biol. Chem. 275 (2000) 39685–39692.
[82] D.M. Heuman, P.B. Hylemon, Z.R. Vlahcevic, J. Lipid Res. 30
(1989) 1161–1171.
[83] P.F. Duckworth, Z.R. Vlahcevic, E.J. Studer, E.C. Gurley, D.M.
Heuman, Z.H. Beg, P.B. Hylemon, J. Biol. Chem. 266 (1991)
9413–9418.
[84] Z.R. Vlahcevic, G. Eggertsen, I. Bjorkhem, P.B. Hylemon, K.
Redford, W.M. Pandak, Gastroenterology 118 (2000) 599–607.
[85] W.M. Pandak, P. Bohdan, C. Franklund, D.H. Mallonee, G. Eggert-
sen, I. Bjorkhem, G. Gil, Z.R. Vlahcevic, P.B. Hylemon, Gastro-
enterology 120 (2001) 1801–1809.
[86] J. Li-Hawkins, E.G. Lund, S.D. Turley, D.W. Russell, J. Biol. Chem.
275 (2000) 16536–16542.
[87] T.A. Spencer, D. Li, J.S. Russel, J.L. Collins, R.K. Bledsoe, T.G.
Consler, L.B. Moore, C.M. Galardi, D.D. McKee, J.T. Moore, M.A.
Watson, D.J. Parks, M.H. Lambert, T.M. Willson, J. Med. Chem. 44
(2001) 886–897.
[88] W.M. Pandak, P.B. Hylemon, S. Ren, D.Marques, G. Gil, K. Redford,
D. Mallonee, Z.R. Vlahcevic, Hepatology 35 (2002) 1400–1408.
[89] G. Schulthess, S. Compassi, M. Werder, C.H. Han, M.C. Phillips, H.
Hauser, Biochemistry 39 (2000) 12623–12631.
[90] M. Werder, C.H. Han, E. Wehrli, D. Bimmler, G. Schulthess, H.
Hauser, Biochemistry 40 (2001) 11643–11650.
[91] J.J. Repa, S.D. Turley, J.A. Lobaccaro, J. Medina, L. Li, K. Lustig,
B. Shan, R.A. Heyman, J.M. Dietschy, D.J. Mangelsdorf, Science
289 (2000) 1524–1529.
[92] W. Drobnik, B. Lindenthal, B. Lieser, M. Ritter, T.C. Weber, G.
Liebisch, U. Giesa, M. Igel, H. Borsukova, C. Buchler, W.P.
Fung-Leung, K. Von Bergmann, G. Schmitz, Gastroenterology
120 (2001) 1203–1211.
[93] K.E. Berge, H. Tian, G.A. Graf, L. Yu, N.V. Grishin, J. Schultz, P.
Kwiterovich, B. Shan, R. Barnes, H.H. Hobbs, Science 290 (2000)
1771–1775.
[94] K. Lu, M.H. Lee, S. Hazard, A. Brooks-Wilson, H. Hidaka, H.
Kojima, L. Ose, A.F. Stalenhoef, T. Mietinnen, I. Bjorkhem, E.
Bruckert, A. Pandya, H.B. Brewer Jr., G. Salen, M. Dean, A.
Srivastava, S.B. Patel, Am. J. Hum. Genet. 69 (2001) 278–290.
[95] M.H. Lee, K. Lu, S. Hazard, H. Yu, S. Shulenin, H. Hidaka, H.
Kojima, R. Allikmets, N. Sakuma, R. Pegoraro, A.K. Srivastava, G.
Salen, M. Dean, S.B. Patel, Nat. Genet. 27 (2001) 79–83.
[96] R.M. Lawn, D.P. Wade, T.L. Couse, J.N. Wilcox, Arterioscler.
Thromb. Vasc. Biol. 21 (2001) 378–385.
[97] E.B. Neufeld, A.T. Remaley, S.J. Demosky, J.A. Stonik, A.M.
Cooney, M. Comly, N.K. Dwyer, M. Zhang, J. Blanchette-Mackie,
S. Santamarina-Fojo, H.B. Brewer Jr., J. Biol. Chem. 276 (2001)
27584–27590.
[98] J. Lee, A. Shirk, J.F. Oram, S.P. Lee, R. Kuver, Biochem. J. 364
(2002) 475–484.
[99] J.J. Repa, K.E. Berge, C. Pomajzl, J.A. Richardson, H. Hobbs, D.J.
Mangelsdorf, J. Biol. Chem. 277 (2002) 18793–18800.
[100] Y. Lange, J. Biol. Chem. 269 (1994) 3411–3414.
[101] J.E. Metherall, K. Waugh, H. Li, J. Biol. Chem. 271 (1996)
2627–2633.
[102] F.J. Field, E. Born, H. Chen, S. Murthy, S.N. Mathur, J. Lipid Res.
36 (1995) 1533–1543.
[103] T.G. Tessner, W.F. Stenson, Biochem. Biophys. Res. Commun. 267
(2000) 565–571.
[104] G.D. Luker, K.R. Nilsson, D.F. Covey, D. Piwnica-Worms, J. Biol.
Chem. 274 (1999) 6979–6991.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–19 15
[105] G.D. Luker, J.L. Dahlheimer, R.E. Ostlund Jr., D. Piwnica-Worms, J.
Lipid Res. 42 (2001) 1389–1394.
[106] R. Chanderbhan, B.J. Noland, T.J. Scallen, G.V. Vahouny, J. Biol.
Chem. 257 (1982) 8928–8934.
[107] E.J. Murphy, F. Schroeder, Biochim. Biophys. Acta 1345 (1997)
283–292.
[108] H. Seltman, W. Diven, M. Rizk, B.J. Noland, R. Chanderbhan, T.J.
Scallen, G. Vahouny, A. Sanghvi, Biochem. J. 230 (1985) 19–24.
[109] B. Lidstrom-Olsson, K. Wikvall, Biochem. J. 238 (1986) 879–884.
[110] J.K. Woodford, S.M. Colles, S. Myers-Payne, J.T. Billheimer, F.
Schroeder, Chem. Phys. Lipids 76 (1995) 73–84.
[111] N.J. Stolowich, A. Frolov, B. Atshaves, E.J. Murphy, C.A. Jolly, J.T.
Billheimer, A.I. Scott, F. Schroeder, Biochemistry 36 (1997)
1719–1729.
[112] A. Frolov, T.H. Cho, J.T. Billheimer, F. Schroeder, J. Biol. Chem.
271 (1996) 31878–31884.
[113] L. Puglielli, A. Rigotti, A.V. Greco, M.J. Santos, F. Nervi, J. Biol.
Chem. 270 (1995) 18723–18726.
[114] C.L. Baum, E.J. Reschly, A.K. Gayen, M.E. Groh, K. Schadick, J.
Biol. Chem. 272 (1997) 6490–6498.
[115] L. Puglielli, A. Rigotti, L. Amigo, L. Nunez, A.V. Greco, M.J. Santos,
F. Nervi, Biochem. J. 317 (1996) 681–687.
[116] M. Fuchs, F. Lammert, D.Q. Wang, B. Paigen, M.C. Carey, D.E.
Cohen, Biochem. J. 336 (1998) 33–37.
[117] S. Zanlungo, L. Amigo, H. Mendoza, J.F. Miquel, C. Vio, J.M. Glick,
A. Rodriguez, K. Kozarsky, V. Quinones, A. Rigotti, F. Nervi, Gas-
troenterology 119 (2000) 1708–1719.
[118] U. Seedorf, M. Raabe, P. Ellinghaus, F. Kannenberg, M. Fobker, T.
Engel, S. Denis, F. Wouters, K.W. Wirtz, R.J. Wanders, N. Maeda,
G. Assmann, Genes Dev. 12 (1998) 1189–1201.
[119] M. Fuchs, A. Hafer, C. Munch, F. Kannenberg, S. Teichmann, J.
Scheibner, E.F. Stange, U. Seedorf, J. Biol. Chem. 22 (2001) 22.
[120] T. Ito, S. Kawata, Y. Imai, H. Kakimoto, J.M. Trzaskos, Y. Matsu-
zawa, Gastroenterology 110 (1996) 1619–1627.
[121] J.R. Jefferson, J.P. Slotte, G. Nemecz, A. Pastuszyn, T.J. Scallen, F.
Schroeder, J. Biol. Chem. 266 (1991) 5486–5496.
[122] J.R. Jefferson, D.M. Powell, Z. Rymaszewski, J. Kukowska-Latallo,
J.B. Lowe, F. Schroeder, J. Biol. Chem. 265 (1990) 11062–11068.
[123] J.K. Woodford, W.D. Behnke, F. Schroeder, Mol. Cell. Biochem.
152 (1995) 51–62.
[124] A.E. Thumser, D.C. Wilton, Biochem. J. 320 (1996) 729–733.
[125] R.G. Anderson, Annu. Rev. Biochem. 67 (1998) 199–225.
[126] B. Dehouck, L. Fenart, M.P. Dehouck, A. Pierce, G. Torpier, R.
Cecchelli, J. Cell Biol. 138 (1997) 877–889.
[127] C. Tiruppathi, W. Song, M. Bergenfeldt, P. Sass, A.B. Malik, J. Biol.
Chem. 272 (1997) 25968–25975.
[128] C.J. Fielding, P.E. Fielding, J. Lipid Res. 38 (1997) 1503–1521.
[129] E.J. Smart, G.A. Graf, M.A. McNiven, W.C. Sessa, J.A. Engelman,
P.E. Scherer, T. Okamoto, M.P. Lisanti, Mol. Cell. Biol. 19 (1999)
7289–7304.
[130] M. Murata, J. Peranen, R. Schreiner, F. Wieland, T.V. Kurzchalia, K.
Simons, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10339–10343.
[131] C. Thiele, M.J. Hannah, F. Fahrenholz, W.B. Huttner, Nat. Cell Biol.
2 (2000) 42–49.
[132] A. Pol, M. Calvo, A. Lu, C. Enrich, Hepatology 29 (1999)
1848–1857.
[133] M. Calvo, C. Enrich, Electrophoresis 21 (2000) 3386–3395.
[134] C.P. Nibbering, Thesis, Department of Gastroenterology, University
of Utrecht, Utrecht, 2001.
[135] A. Bist, P.E. Fielding, C.J. Fielding, Proc. Natl. Acad. Sci. U. S. A.
94 (1997) 10693–10698.
[136] E.J. Smart, Y. Ying, W.C. Donzell, R.G. Anderson, J. Biol. Chem.
271 (1996) 29427–29435.
[137] P.E. Fielding, C.J. Fielding, Biochemistry 34 (1995) 14288–14292.
[138] J. Babitt, B. Trigatti, A. Rigotti, E.J. Smart, R.G. Anderson, S. Xu,
M. Krieger, J. Biol. Chem. 272 (1997) 13242–13249.
[139] J.F. Miquel, A. Rigotti, S.F. Zanlungo, L. Amigo, H. Mendoza,
M. Moreno, J. Garrido, P.F. Arias, F. Nervi, Gastroenterology 116
(1999) A1246.
[140] M. Drab, P. Verkade, M. Elger, M. Kasper, M. Lohn, B. Lauterbach,
J. Menne, C. Lindschau, F. Mende, F.C. Luft, A. Schedl, H. Haller,
T.V. Kurzchalia, Science 293 (2001) 2449–2452.
[141] B. Razani, J.A. Engelman, X.B. Wang, W. Schubert, X.L. Zhang,
C.B. Marks, F. Macaluso, R.G. Russell, M. Li, R.G. Pestell, D. Di
Vizio, H. Hou Jr., B. Kneitz, G. Lagaud, G.J. Christ, W. Edelmann,
M.P. Lisanti, J. Biol. Chem. 276 (2001) 38121–38138.
[142] P.G. Frank, A. Pedraza, D.E. Cohen, M.P. Lisanti, Biochemistry 40
(2001) 10892–10900.
[143] E.D. Carstea, J.A. Morris, K.G. Coleman, S.K. Loftus, D. Zhang, C.
Cummings, J. Gu, M.A. Rosenfeld, W.J. Pavan, D.B. Krizman, J.
Nagle, M.H. Polymeropoulos, S.L. Sturley, Y.A. Ioannou, M.E. Hig-
gins, M. Comly, A. Cooney, A. Brown, C.R. Kaneski, E.J. Blanch-
ette-Mackie, N.K. Dwyer, E.B. Neufeld, T.Y. Chang, L. Liscum,
D.A. Tagle, et al., Science 277 (1997) 228–231.
[144] P.G. Pentchev, R.O. Brady, E.J. Blanchette-Mackie, M.T. Vanier,
E.D. Carstea, C.C. Parker, E. Goldin, C.F. Roff, Biochim. Biophys.
Acta 1225 (1994) 235–243.
[145] L. Amigo, H. Mendoza, J. Castro, V. Quinones, J.F. Miquel, S.
Zanlungo, Hepatology 36 (2002) 819–828.
[146] R. Williamson, D. Lee, J. Hagaman, N. Maeda, Proc. Natl. Acad.
Sci. U. S. A. 89 (1992) 7134–7138.
[147] C.D. Jolley, J.M. Dietschy, S.D. Turley, Hepatology 32 (2000)
1309–1316.
[148] A. Rigotti, L. Amigo, V. Quinones, S. Zanlungo, M. Arrese, J.F.
Miquel, F. Nervi, et al., Gastroenterology 116 (1999) L0379.
[149] J. Herz, T.E. Willnow, Curr. Opin. Lipidol. 6 (1995) 97–103.
[150] E. Sehayek, S. Shefer, L.B. Nguyen, J.G. Ono, M. Merkel, J.L.
Breslow, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3433–3437.
[151] L. Amigo, V. Quinones, P. Mardones, S. Zanlungo, J.F. Miquel, F.
Nervi, A. Rigotti, Gastroenterology 118 (2000) 772–779.
[152] F. Kuipers, J.M. Vanree, M.H. Hofker, H. Wolters, G.I. Veld, R.
Havinga, R.J. Vonk, H.M.G. Princen, L.M. Havekes, Hepatology
24 (1996) 241–247.
[153] T. Juvonen, K. Kervinen, M.I. Kairaluoma, L.H. Lajunen, Y.A. Ke-
saniemi, Gastroenterology 104 (1993) 1806–1813.
[154] A. Bertomeu, E. Ros, D. Zambon, M. Vela, R.M. Perez-Ayuso, E.
Targarona, M. Trias, C. Sanllehy, E. Casals, J.M. Ribo, Gastro-
enterology 111 (1996) 1603–1610.
[155] K.J. Van Erpecum, G.P. Van Berge-henegouwen, E.R. Eckhardt, P.
Portincasa, B.J. Van De Heijning, G.M. Dallinga-Thie, A.K. Groen,
Hepatology 27 (1998) 1508–1516.
[156] S. Fischer, M.H. Dolu, B. Zundt, G. Meyer, S. Geisler, D. Jungst,
Eur. J. Clin. Invest. 31 (2001) 789–795.
[157] Y.A. Kesaniemi, C. Ehnholm, T.A. Miettinen, J. Clin. Invest. 80
(1987) 578–581.
[158] T. Miettinen, H. Gylling, H. Vanhanen, A. Ollus, Arterioscler.
Thromb. Vasc. Biol. 12 (1992) 1044–1052.
[159] S.L. Acton, P.E. Scherer, H.F. Lodish, M. Krieger, J. Biol. Chem.
269 (1994) 21003–21009.
[160] S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, M.
Krieger, Science 271 (1996) 518–520.
[161] P.J. Voshol, M. Schwarz, A. Rigotti, M. Krieger, A.K. Groen, F.
Kuipers, Biochem. J. 356 (2001) 317–325.
[162] M. Krieger, K. Kozarsky, Curr. Opin. Lipidol. 10 (1999) 491–497.
[163] B. Trigatti, A. Rigotti, M. Krieger, Curr. Opin. Lipidol. 11 (2000)
123–131.
[164] D.K. Spady, D.M. Kearney, H.H. Hobbs, J. Lipid Res. 40 (1999)
1384–1394.
[165] M. Krieger, Annu. Rev. Biochem. 68 (1999) 523–558.
[166] D.L. Silver, N. Wang, X. Xiao, A.R. Tall, J. Biol. Chem. 276 (2001)
25287–25293.
[167] A.S. Plump, N. Azrolan, H. Odaka, L. Wu, X. Jiang, A. Tall, S.
Eisenberg, J.L. Breslow, J. Lipid Res. 38 (1997) 1033–1047.
[168] S.J. Robins, J.M. Fasulo, J. Clin. Invest. 99 (1997) 380–384.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–1916
[169] K.F. Kozarsky, M.H. Donahee, A. Rigotti, S.N. Iqbal, E.R. Edelman,
M. Krieger, Nature 387 (1997) 414–417.
[170] D.E. Cohen, Curr. Opin. Lipidol. 10 (1999) 295–302.
[171] A. Rigotti, B.L. Trigatti, M. Penman, H. Rayburn, J. Herz, M.
Krieger, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12610–12615.
[172] B. Trigatti, H. Rayburn, M. Vinals, A. Braun, H. Miettinen, M.
Penman, M. Hertz, M. Schrenzel, L. Amigo, A. Rigotti, M. Krieger,
Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9322–9327.
[173] P. Mardones, V. Quinones, L. Amigo, M. Moreno, J.F. Miquel, M.
Schwarz, H.E. Miettinen, B. Trigatti, M. Krieger, S. VanPatten, D.E.
Cohen, A. Rigotti, J. Lipid Res. 42 (2001) 170–180.
[174] R.P.J.O. Elferink, C.M.G. Frijters, C. Paulusma, A.K. Groen, J.
Hepatol. 24 (Suppl. 1994; 1) (1996) 94–99, 12.
[175] G. Bouchard, H.M. Nelson, F. Lammert, L.B. Rowe, M.C. Carey, B.
Paigen, Mamm. Genome 10 (1999) 1070–1074.
[176] R. Wang, M. Salem, I.M. Yousef, B. Tuchweber, P. Lam, S.J. Childs,
C.D. Helgason, C. Ackerley, M.J. Phillips, V. Ling, Proc. Natl.
Acad. Sci. U. S. A. 98 (2001) 2011–2016.
[177] C.M. Frijters, R. Ottenhoff, M.J. van Wijland, C.M. van Nieuwkerk,
A.K. Groen, R.P. Oude Elferink, Biochem. J. 321 (1997) 389–395.
[178] S.S. Strautnieks, L.N. Bull, A.S. Knisely, S.A. Kocoshis, N. Dahl, H.
Arnell, E. Sokal, K. Dahan, S. Childs, V. Ling, M.S. Tanner, A.F.
Kagalwalla, A. Nemeth, J. Pawlowska, A. Baker, G. Mieli-Vergani,
N.B. Freimer, R.M. Gardiner, R.J. Thompson, Nat. Genet. 20
(1998) 233–238.
[179] J.J. Smit, A.H. Schinkel, R.P. Oude Elferink, A.K. Groen, E.
Wagenaar, L. van Deemter, C.A. Mol, R. Ottenhoff, N.M. van
der Lugt, M.A. van Roon, M.A. van der Valk, G.J.A. Offerhaus,
A.J.M. Berns, P. Borst, Cell 75 (1993) 451–462.
[180] S. Ruetz, P. Gros, J. Biol. Chem. 270 (1995) 25388–25395.
[181] G.J. Hooiveld, T.A. Vos, G.L. Scheffer, H. Van Goor, H. Koning, V.
Bloks, A.E. Loot, D.K. Meijer, P.L. Jansen, F. Kuipers, M. Muller,
Gastroenterology 117 (1999) 678–687.
[182] J. Chianale, V. Vollrath, A.M. Wielandt, L. Amigo, A. Rigotti, F.
Nervi, S. Gonzalez, L. Andrade, M. Pizarro, L. Accatino, Biochem.
J. 314 (1996) 781–786.
[183] M. Carrella, D. Feldman, S. Cogoi, A. Csillaghy, P.A. Weinhold,
Hepatology 29 (1999) 1825–1832.
[184] S. Miranda, V. Vollrath, A.M. Wielandt, G. Loyola, M. Bronfman, J.
Chianale, J. Hepatol. 26 (1997) 1331–1339.
[185] M.N. Cayen, D. Dvornik, J. Lipid Res. 20 (1979) 162–174.
[186] L. Accatino, M. Pizarro, N. Solis, C.S. Koenig, Hepatology 28
(1998) 129–140.
[187] A. Thewles, R.A. Parslow, R. Coleman, Biochem. J. 291 (1993)
793–798.
[188] X. Wang, R. Sato, M.S. Brown, X. Hua, J.L. Goldstein, Cell 77
(1994) 53–62.
[189] X. Hua, J. Sakai, M.S. Brown, J.L. Goldstein, J. Biol. Chem. 271
(1996) 10379–10384.
[190] J. Sakai, E.A. Duncan, R.B. Rawson, X. Hua, M.S. Brown, J.L.
Goldstein, Cell 85 (1996) 1037–1046.
[191] C. Yokoyama, X. Wang, M.R. Briggs, A. Admon, J. Wu, X. Hua,
J.L. Goldstein, M.S. Brown, Cell 75 (1993) 187–197.
[192] H. Shimano, I. Shimomura, R.E. Hammer, J. Herz, J.L. Goldstein,
M.S. Brown, J.D. Horton, J. Clin. Invest. 100 (1997) 2115–2124.
[193] H. Shimano, J.D. Horton, R.E. Hammer, I. Shimomura, M.S. Brown,
J.L. Goldstein, J. Clin. Invest. 98 (1996) 1575–1584.
[194] J.D. Horton, I. Shimomura, M.S. Brown, R.E. Hammer, J.L.
Goldstein, H. Shimano, J. Clin. Invest. 101 (1998) 2331–2339.
[195] B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, D.J. Mangelsdorf,
Nature 383 (1996) 728–731.
[196] J.M. Lehmann, S.A. Kliewer, L.B. Moore, T.A. Smith-Oliver, B.B.
Oliver, J.L. Su, S.S. Sundseth, D.A. Winegar, D.E. Blanchard, T.A.
Spencer, T.M. Willson, J. Biol. Chem. 272 (1997) 3137–3140.
[197] B.M. Forman, B. Ruan, J. Chen, G.J. Schroepfer Jr., R.M. Evans,
Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10588–10593.
[198] J.R. Schultz, H. Tu, A. Luk, J.J. Repa, J.C. Medina, L. Li, S.
Schwendner, S. Wang, M. Thoolen, D.J. Mangelsdorf, K.D. Lustig,
B. Shan, Genes Dev. 14 (2000) 2831–2838.
[199] J.J. Repa, G. Liang, J. Ou, Y. Bashmakov, J.M. Lobaccaro, I.
Shimomura, B. Shan, M.S. Brown, J.L. Goldstein, D.J. Mangelsdorf,
Genes Dev. 14 (2000) 2819–2830.
[200] P. Costet, Y. Luo, N. Wang, A.R. Tall, J. Biol. Chem. 275 (2000)
28240–28245.
[201] A. Venkateswaran, J.J. Repa, J.M. Lobaccaro, A. Bronson, D.J. Man-
gelsdorf, P.A. Edwards, J. Biol. Chem. 275 (2000) 14700–14707.
[202] Y. Luo, C.P. Liang, A.R. Tall, J. Biol. Chem. 276 (2001)
24767–24773.
[203] B.A. Laffitte, J.J. Repa, S.B. Joseph, D.C. Wilpitz, H.R. Kast, D.J.
Mangelsdorf, P. Tontonoz, Proc. Natl. Acad. Sci. U. S. A. 98 (2001)
507–512.
[204] T. Engel, S. Lorkowski, A. Lueken, S. Rust, B. Schluter, G. Berger,
P. Cullen, G. Assmann, Biochem. Biophys. Res. Commun. 288
(2001) 483–488.
[205] S. Alberti, G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M.
Rudling, B. Angelin, I. Bjorkhem, S. Pettersson, J.A. Gustafsson, J.
Clin. Invest. 107 (2001) 565–573.
[206] B.M. Forman, E. Goode, J. Chen, A.E. Oro, D.J. Bradley, T. Perl-
mann, D.J. Noonan, L.T. Burka, T. McMorris, W.W. Lamph, et al.,
Cell 81 (1995) 687–693.
[207] M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A.
Luk, M.V. Hull, K.D. Lustig, D.J. Mangelsdorf, B. Shan, Science
284 (1999) 1362–1365.
[208] D.J. Parks, S.G. Blanchard, R.K. Bledsoe, G. Chandra, T.G. Consler,
S.A. Kliewer, J.B. Stimmel, T.M. Willson, A.M. Zavacki, D.D.
Moore, J.M. Lehmann, Science 284 (1999) 1365–1368.
[209] H. Wang, J. Chen, K. Hollister, L.C. Sowers, B.M. Forman, Mol.
Cell 3 (1999) 543–553.
[210] P.B. Hylemon, R.T. Stravitz, Z.R. Vlahcevic, Prog. Liver Dis. 12
(1994) 99–120.
[211] R.J. Bahar, A. Stolz, Gastroenterol. Clin. North Am. 28 (1999)
27–58.
[212] D.F. Jelinek, S. Andersson, C.A. Slaughter, D.W. Russell, J. Biol.
Chem. 265 (1990) 8190–8197.
[213] V. Cattori, U. Eckhardt, B. Hagenbuch, Biochim. Biophys. Acta
1445 (1999) 154–159.
[214] R.M. Green, F. Hoda, K.L. Ward, Gene 241 (2000) 117–123.
[215] M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D.J.
Mangelsdorf, F.J. Suchy, J. Biol. Chem. 276 (2001) 28857–28865.
[216] M.W. Crossman, S.M. Hauft, J.I. Gordon, J. Cell Biol. 126 (1994)
1547–1564.
[217] J. Grober, I. Zaghini, H. Fujii, S.A. Jones, S.A. Kliewer, T.M.
Willson, T. Ono, P. Besnard, J. Biol. Chem. 274 (1999)
29749–29754.
[218] B.A. Laffitte, H.R. Kast, C.M. Nguyen, A.M. Zavacki, D.D. Moore,
P.A. Edwards, J. Biol. Chem. 275 (2000) 10638–10647.
[219] N.L. Urizar, D.H. Dowhan, D.D. Moore, J. Biol. Chem. 275 (2000)
39313–39317.
[220] C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, F.J.
Gonzalez, Cell 102 (2000) 731–744.
[221] L.A. Denson, E. Sturm, W. Echevarria, T.L. Zimmerman, M.
Makishima, D.J. Mangelsdorf, S.J. Karpen, Gastroenterology 121
(2001) 140–147.
[222] M. Nitta, S. Ku, C. Brown, A.Y. Okamoto, B. Shan, Proc. Natl.
Acad. Sci. U. S. A. 96 (1999) 6660–6665.
[223] Y.K. Lee, K.L. Parker, H.S. Choi, D.D. Moore, J. Biol. Chem. 274
(1999) 20869–20873.
[224] A. del Castillo-Olivares, G. Gil, Nucleic Acids Res. 28 (2000)
3587–3593.
[225] W. Seol, H.S. Choi, D.D. Moore, Science 272 (1996) 1336–1339.
[226] L. Johansson, J.S. Thomsen, A.E. Damdimopoulos, G. Spyrou, J.A.
Gustafsson, E. Treuter, J. Biol. Chem. 274 (1999) 345–353.
[227] L. Johansson, A. Bavner, J.S. Thomsen, M. Farnegardh, J.A.
Gustafsson, E. Treuter, Mol. Cell. Biol. 20 (2000) 1124–1133.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–19 17
[228] Y.K. Lee, H. Dell, D.H. Dowhan, M. Hadzopoulou-Cladaras, D.D.
Moore, Mol. Cell. Biol. 20 (2000) 187–195.
[229] S.S. Lee, T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz,
P.M. Fernandez-Salguero, H. Westphal, F.J. Gonzalez, Mol. Cell.
Biol. 15 (1995) 3012–3022.
[230] T. Aoyama, J.M. Peters, N. Iritani, T. Nakajima, K. Furihata, T.
Hashimoto, F.J. Gonzalez, J. Biol. Chem. 273 (1998) 5678–5684.
[231] M.C. Hunt, Y.Z. Yang, G. Eggertsen, C.M. Carneheim, M. Gaf-
vels, C. Einarsson, S.E. Alexson, J. Biol. Chem. 275 (2000)
28947–28953.
[232] J.M. Peters, N. Hennuyer, B. Staels, J.C. Fruchart, C. Fievet, F.J.
Gonzalez, J. Auwerx, J. Biol. Chem. 272 (1997) 27307–27312.
[233] D. Stahlberg, E. Reihner, M. Rudling, L. Berglund, K. Einarsson, B.
Angelin, Hepatology 21 (1995) 1025–1030.
[234] S.M. Grundy, E.H. Ahrens Jr., G. Salen, P.H. Schreibman, P.J. Nes-
tel, J. Lipid Res. 13 (1972) 531–551.
[235] Y.A. Kesaniemi, S.M. Grundy, JAMA 251 (1984) 2241–2246.
[236] F.X. Caroli-Bosc, P. Le Gall, P. Pugliese, B. Delabre, C. Caroli-Bosc,
J.F. Demarquay, J.P. Delmont, P. Rampal, J.C. Montet, Dig. Dis. Sci.
46 (2001) 540–544.
[237] S.M. Post, H. Duez, P.P. Gervois, B. Staels, F. Kuipers, H.M.
Princen, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1840–1845.
[238] T.E. Akiyama, J.M. Ward, F.J. Gonzalez, J. Biol. Chem. 275 (2000)
27117–27122.
[239] D.Q. Shih, M. Bussen, E. Sehayek, M. Ananthanarayanan, B.L.
Shneider, F.J. Suchy, S. Shefer, J.S. Bollileni, F.J. Gonzalez, J.L.
Breslow, M. Stoffel, Nat. Genet. 27 (2001) 375–382.
[240] N.J. Sund, S.L. Ang, S.D. Sackett, W. Shen, N. Daigle, M.A.
Magnuson, K.H. Kaestner, Mol. Cell. Biol. 20 (2000) 5175–5183.
[241] G.P. Hayhurst, Y.H. Lee, G. Lambert, J.M. Ward, F.J. Gonzalez,
Mol. Cell. Biol. 21 (2001) 1393–1403.
[242] A. del Castillo-Olivares, G. Gil, Nucleic Acids Res. 29 (2001)
4035–4042.
[243] M. Zhang, J.Y. Chiang, J. Biol. Chem. 276 (2001) 41690–41699.
[244] D. Stroup, J.Y. Chiang, J. Lipid Res. 41 (2000) 1–11.
[245] R. Garuti, M.A. Croce, L. Piccinini, R. Tiozzo, S. Bertolini, S.
Calandra, Gene 283 (2002) 133–143.
[246] E.A. Kirk, G.L. Moe, M.T. Caldwell, J.A. Lernmark, D.L. Wilson,
R.C. LeBoeuf, J. Lipid Res. 36 (1995) 1522–1532.
[247] B. Khanuja, Y.C. Cheah, M. Hunt, P.M. Nishina, D.Q. Wang, H.W.
Chen, J.T. Billheimer, M.C. Carey, B. Paigen, Proc. Natl. Acad. Sci.
U. S. A. 92 (1995) 7729–7733.
[248] D.Q. Wang, B. Paigen, M.C. Carey, J. Lipid Res. 38 (1997)
1395–1411.
[249] A.F. Hofmann, S.M. Grundy, J.M. Lachin, S.P. Lan, R.A. Baum,
R.F. Hanson, T. Hersh, N.C. Hightower Jr., J.W. Marks, H. Mekhjian,
R.A. Shaefer, R.D. Soloway, J.L. Thistle, F.B. Thomas, M.P. Tyor,
Gastroenterology 83 (1982) 738–752.
[250] M. Alexander, O.W. Portman, Hepatology 7 (1987) 257–265.
[251] H. Wittenburg, F. Lammert, D.Q. Wang, G.A. Churchill, R. Li, G.
Bouchard, M.C. Carey, B. Paigen, Physiol. Genomics 8 (2002)
67–77.
[252] G.C. Bouchard, H.C. Chao, F. Lammert, D.Q.-H. Wang, B. Paigen,
Hepatology 28 (1998) 502A.
[253] G.C. Bouchard, M.C. Carey, B. Paigen, Gastroenterology 2000
(2000) A1017.
[254] W. Kratzer, R.A. Mason, V. Kachele, J. Clin. Ultrasound 27 (1999)
1–7.
[255] M. Brett, D.J. Barker, Int. J. Epidemiol. 5 (1976) 335–341.
[256] M. Sugimoto, T. Abei, H. Kameda, Jpn. J. Med. 22 (1983)
90–94.
[257] F. Nervi, I. Duarte, G. Gomez, G. Rodriguez, G. Del Pino, O.
Ferrerio, C. Covarrubias, V. Valdivieso, M.I. Torres, A. Urzua, Int. J.
Cancer 41 (1988) 657–660.
[258] J.F. Miquel, C. Covarrubias, L. Villaroel, G. Mingrone, A.V. Greco,
L. Puglielli, P. Carvallo, G. Marshall, G. Del Pino, F. Nervi, Gastro-
enterology 115 (1998) 937–946.
[259] P.L. Moro, W. Checkley, R.H. Gilman, G. Lescano, J.J. Bonilla, B.
Silva, H.H. Garcia, Am. J. Gastroenterol. 94 (1999) 153–158.
[260] P.L. Moro, W. Checkley, R.H. Gilman, L. Cabrera, A.G. Lescano,
J.J. Bonilla, B. Silva, Gut 46 (2000) 569–573.
[261] A.P. Brasca, S.M. Pezzotto, D. Berli, R. Villavicencio, O. Fay, M.P.
Gianguzzo, L. Poletto, Dig. Dis. Sci. 45 (2000) 2392–2398.
[262] K.R. Maurer, J.E. Everhart, T.M. Ezzati, R.S. Johannes, W.C.
Knowler, D.L. Larson, R. Sanders, T.H. Shawker, H.P. Roth, Gastro-
enterology 96 (1989) 487–492.
[263] A.K. Diehl, W.H. Schwesinger, D.R. Holleman Jr., J.B. Chapman,
W.E. Kurtin, Dig. Dis. Sci. 39 (1994) 2223–2228.
[264] R.E. Sampliner, P.H. Bennett, L.J. Comess, F.A. Rose, T.A. Burch,
N. Engl. J. Med. 283 (1970) 1358–1364.
[265] C.N. Williams, J.L. Johnston, K.L. Weldon, Can. Med. Assoc. J. 117
(1977) 758–760.
[266] L.J. Bennion, W.C. Knowler, D.M. Mott, A.M. Spagnola, P.H. Ben-
nett, N. Engl. J. Med. 300 (1979) 873–876.
[267] K.M. Weiss, R.E. Ferrell, C.L. Hanis, P.N. Styne, Am. J. Hum.
Genet. 36 (1984) 1259–1278.
[268] C.N. Williams, J.L. Johnston, Can. Med. Assoc. J. 122 (1980)
664–668.
[269] E.A. Bortnichak, D.H. Freeman Jr., A.M. Ostfeld, W.P. Castelli,
W.B. Kannel, M. Feinleib, P.M. McNamara, Am. J. Epidemiol.
121 (1985) 19–30.
[270] J. Ratner, A. Lisbona, M. Rosenbloom, M. Palayew, S. Szabolcsi, T.
Tupaz, JAMA 265 (1991) 902–903.
[271] J.L. Thistle, L.J. Schoenfield, N. Engl. J. Med. 284 (1971) 177–181.
[272] G.P.B. Huddy, Lancet 269 (1925) 276–278.
[273] G. Ko˜rner, Z. Menschl. Vererb. Konstitutionsl. 20 (1937) 528–582.
[274] T.R. Littler, G.R. Ellis, Br. Med. J. 1 (1952) 842–844.
[275] C.E. Jackson, B.C. Gay, Surgery 46 (1959) 853–857.
[276] W. van der Linden, G. Lindelo¨f, Acta Genet. Basel 15 (1965)
159–164.
[277] W. van der Linden, N. Westlin, Acta Genet. Basel 16 (1966)
377–382.
[278] W. van der Linden, N. Simonson, Hum. Hered. 23 (1973) 123–127.
[279] T. Gilat, C. Feldman, Z. Halpern, M. Dan, S. Bar-Meir, Gastroenter-
ology 84 (1983) 242–246.
[280] S.K. Sarin, V.S. Negi, R. Dewan, S. Sasan, A. Saraya, Hepatology
22 (1995) 138–141.
[281] R.G. Danzinger, H. Gordon, L.J. Schoenfield, J.L. Thistle, Mayo
Clin. Proc. 47 (1972) 762–766.
[282] B. Harvald, M. Hauge, Dan. Med. Bull. 3 (1956) 150–158.
[283] R. Doig, Med. J. Aust. 44 (1957) 716–717.
[284] R. Doig, F. Pitman, Med. J. Aust. 44 (1957) 612–617.
[285] Y. Antero Kesaniemi, M. Koskenvuo, M. Vuoristo, T.A. Miettinen,
Gut 30 (1989) 1750–1756.
[286] E. Jacquemin, J.M. De Vree, D. Cresteil, E.M. Sokal, E. Sturm, M.
Dumont, G.L. Scheffer, M. Paul, M. Burdelski, P.J. Bosma, O.
Bernard, M. Hadchouel, R.P. Elferink, Gastroenterology 120 (2001)
1448–1458.
[287] J.M. de Vree, E. Jacquemin, E. Sturm, D. Cresteil, P.J. Bosma, J.
Aten, J.F. Deleuze, M. Desrochers, M. Burdelski, O. Bernard, R.P.
Oude Elferink, M. Hadchouel, Proc. Natl. Acad. Sci. U. S. A. 95
(1998) 282–287.
[288] P.H. Dixon, N.Weerasekera, K.J. Linton, O. Donaldson, J. Chambers,
E. Egginton, J. Weaver, C. Nelson-Piercy, M. de Swiet, G. Warnes, E.
Elias, C.F. Higgins, D.G. Johnston, M.I. McCarthy, C. Williamson,
Hum. Mol. Genet. 9 (2000) 1209–1217.
[289] E. Jacquemin, D. Cresteil, S. Manouvrier, O. Boute, M. Hadchouel,
Lancet 353 (1999) 210–211.
[290] D. Ortiz, I.M. Arias, Gastroenterology 120 (2001) 1549–1552.
[291] M. Niemi, K. Kervinen, A. Rantala, H. Kauma, M. Paivansalo, M.J.
Savolainen, M. Lilja, Y.A. Kesaniemi, Gut 44 (1999) 557–562.
[292] T. Juvonen, M.J. Savolainen, M.I. Kairaluoma, L.H. Lajunen, S.E.
Humphries, Y.A. Kesaniemi, J. Lipid Res. 36 (1995) 804–812.
[293] T. Han, Z. Jiang, G. Suo, S. Zhang, Clin. Genet. 57 (2000) 304–308.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–1918
[294] G. Nardone, I.A. Ferber, L.J. Miller, Hepatology 22 (1995)
1751–1753.
[295] R.C. Stern, F.C. Rothstein, C.F. Doershuk, J. Pediatr. Gastroenterol.
Nutr. 5 (1986) 35–40.
[296] H. Rovsing, K. Sloth, Acta Radiol., Diagn. (Stockh.) 14 (1973)
588–592.
[297] P.R. L’Heureux, J.N. Isenberg, H.L. Sharp, W.J. Warwick, AJR Am.
J. Roentgenol. 128 (1977) 953–956.
[298] E. Toscano, V. Trivellini, G. Andria, Arch. Dis. Child. 85 (2001)
242–243.
[299] J. Perez-Calvo, M. Bernal, P. Giraldo, M.A. Torralba, F. Civeira, M.
Giralt, M. Pocovi, Eur. J. Med. Res. 5 (2000) 231–235.
[300] C.C. Roy, A.M. Weber, C.L. Morin, J.C. Combes, D. Nussle, A.
Megevand, R. Lasalle, N. Engl. J. Med. 297 (1977) 1301–1305.
[301] M. Angelico, C. Gandin, P. Canuzzi, S. Bertasi, A. Cantafora, A. De
Santis, S. Quattrucci, M. Antonelli, Hepatology 14 (1991) 768–775.
[302] J. Elias Pollina, J. Garate, E. Martin Bejarano, J.C. Vitoria, A. Sojo,
J. Ubalde, J.A. Perez Marrodan, J.E. Olivera, P. Zubillaga, P. Fer-
nandez, et al., Cir. Pediatr. 5 (1992) 96–100.
[303] D.J. Aughton, P. Gibson, A. Cacciarelli, Clin. Pediatr. (Phila.) 31
(1992) 650–652.
[304] F.M. Aynaci, E. Erduran, H. Mocan, A. Okten, A.O. Sarpkaya, Acta
Paediatr. 84 (1995) 711–712.
A. Kosters et al. / Biochimica et Biophysica Acta 1637 (2003) 1–19 19
